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ABSTRACT 
Gout was historically known as the king of diseases and disease of kings, reserved for 
those of wealthy, extravagant lifestyles. Far from being resigned to history books, gout 
is on the rise worldwide and in New Zealand – where we have the highest rate of gout 
in the world – Maori and Polynesian populations have a greatly elevated risk of 
experiencing the debilitating disease. 
Gout arises as a direct result of increased urate in the blood, and as such many 
studies worldwide have investigated gout, using serum urate levels as a proxy 
measure. Recently, two important genome-wide association studies were published – 
these compare the genomes of those with elevated serum urate to the genomes of 
control subjects and identify differences. Single nucleotide polymorphisms (SNPs) 
were identified upstream of MAF, a gene that had not before been associated with 
serum urate levels. These SNPs were in what is known as a non-protein-coding 
region, which often play an important role in gene regulation. 
MAF is a transcription factor that is expressed in the lens of the eye and immune 
cells, and many studies into MAF have focused on these aspects. However, MAF has 
also been shown to be expressed in the developing kidney (in zebrafish and mice), 
which is of great relevance in a study of gout. Therefore, it was hypothesised that one 
or more of the SNPs upstream of MAF alter regulation of the MAF gene in the 
kidney, resulting in a change in serum urate levels. 
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An in silico analysis was carried out, using publicly available datasets to produce 
candidate causal variants upstream of the MAF gene. When multiple datasets were 
combined and meta-analysed, no specific candidates were produced – however, 
some SNPs approached significance. This is noteworthy in such a small sample set (n 
= 18,503, versus 71,149 and >140,000 in the GWAS analyses), and the analysis 
needs to be repeated on a larger scale. 
Based on ENCODE annotations, candidate SNPs were selected in areas that looked 
to be involved in regulation of gene expression. To investigate the putative cis-
regulatory role of SNPs, reporter constructs were used in human cell lines. This 
enhancer assay indicated that one element acts to enhance gene expression, and that 
the SNPs within this element increased this effect. 
Finally, a chromosome conformation capture (3C) experiment aimed to determine 
the interactions occurring between the MAF promoter and these upstream regions, 
but unfortunately the results were inconclusive. 
This study contributes to a growing field of research investigating the effects of non-
coding DNA on gene expression, in the context of an important disease affecting the 
lives of New Zealanders everyday. Future findings may provide a novel mechanism 
by which non-coding variants affect serum urate levels in a system that has not 
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Gout is an ancient disease and was first recognised by the Egyptians in 2640 BC, with 
Hippocratic written evidence dating back to 400 BC. Epidemics have been reported 
since that time, typically coinciding with cultures famous for rich, high-purine diets – 
notably, the ancient Romans and 19th century England – leading to gout’s reputation 
as “the king of diseases and disease of kings”[3, 4]. Prevalence is now rising again 
across the world [3-5] – between 1970 and 1990, prevalence of gout rose from 0.3% 
to 1.0% in England, with similar reports from the US [3]. 
While environmental risk factors are reasonably well understood, genetic risk factors 
have only been identified in recent years. Genome-wide association studies (GWAS) 
provide a uniquely powerful system for identifying associations between gout and 
genetic variants, but these variants are often in non-coding DNA and do not tell us 
anything about the causal mechanism of the association. Non-coding DNA often has 
a regulatory role, and further research will allow us to develop our understanding of a 
genetically complex disease such as gout. 
1.1 GOUT 
1.1.1 Uric acid, pathophysiology and diagnosis 
Gout is the most common form of inflammatory arthritis to afflict men, typically over 
the age of 40, with 1-2% of the US population affected [3, 6]. The major risk factor 
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for gout is chronic elevated serum urate (interchangeably referred to as uric acid in 
the literature). 
Uric acid is the end product of purine metabolism [6] and there is little pure urate in 
the human diet [3]. Uric acid is mostly produced in the liver, with 70% of the 
metabolised purines being endogenous (i.e. originating from nucleic acids in cells) 
and the rest coming from dietary purine [3, 4]. Urate levels therefore depend on the 
balance of purine ingestion, purine synthesis and recycling, and the activity of 
xanthine oxidase. Xanthine oxidase [7] catalyses the final conversion of purine 
metabolite into uric acid, and is found in the peroxisomes of most cells [8] [3]. 
Uricase is an enzyme that is present in most other animals, but one that humans and 
higher primates have lost. Uricase converts uric acid into the highly soluble allantoin, 
and as a result most other mammals have uric acid levels of less than 60 µmol/L [3, 4, 
8, 9]; this could explain why even healthy individuals have serum urate levels so close 
to physiological saturation [8]. Hyperuricemia is typically caused by decreased renal 
excretion [3, 4, 6]. 
Serum urate (at or above physiological saturation level, 380 µmol/L) can 
supersaturate local tissues, leading to precipitation of the acid with sodium (found in 
copious amounts in the extracellular compartment) into monosodium urate (MSU) 
crystals at the joints. Most commonly, urate precipitates at the big toe, but the mid-
foot, ankle, knee, fingers, wrist and elbow are all known to be affected by gout [3-6, 8, 
9]. MSU crystals are pro-inflammatory, triggering and sustaining an inflammatory 
response. Monocytes can phagocytose the crystals, an activation pathway begins and 
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leads to interleukin 1β (IL-1β) maturation and secretion. IL-1β appears to be a key 
mediator in the immune response to MSU crystals as it leads to production of pro-
inflammatory molecules, leading the inflammatory response that is central to a gout 
attack [3, 8]. 
Hyperuricemia is necessary but not sufficient for gout – according to Roddy et al. 
(2007), only 22% of people with hyperuricemia develop gout after 5 years [4]. The 
authors also claim that it is unclear as to why some with hyperuricemia are more 
susceptible to gout than others, but attributes some of the blame to a probable cause: 
co-presentation of osteoarthritis. However, in 2013 Roddy et al. refer to the 
incidence of gout in those with hyperuricemia as 10%, while others acknowledge the 
spectrum of incidence that correlates to the spectrum of serum urate concentration – 
0.5% incidence for those with serum urate between 420 µmol/L and 530 µmol/L, and 
4.5% incidence for serum urate concentration above 540 µmol/L [3, 9]. 
Knowing the incidence of gout in those presenting with hyperuricemia is vital – it 
conveys risk, and as hyperuricemia is so often used as a proxy measurement of gout 
in empirical studies, it is fundamental that we can translate data from hyperuricemic 
individuals to gout patients and examine how similar these two groups are. The 
difficulty in agreeing on a figure may come down to differences in study populations, 
or more simply may be as a result of the method of diagnosing gout. The gold 
standard of gout diagnosis to date is identifying MSU crystals under a microscope, 
from patient samples of synovial fluid or tophi (the hard, impacted crystals that form 
during chronic gout)[6, 10]. Patient reports of symptoms are often non-specific to 
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gout – other forms of arthritis cannot be ruled out. Other imaging and diagnostic 
techniques are emerging, but currently the simplest and most cost-effective tool is a 
blood test, which measures hyperuricemia. Therefore, it is essential to establish 
incidence of gout in conditions of hyperuricemia. 
Measuring serum urate is a useful tool when treating a patient for gout, particularly 
when measuring the effectiveness of urate-lowering therapy (ULT). This is known as 
“treating to target”, whereby serum urate is monitored as urate-lowering drugs are 
prescribed, the target typically 360 µmol/L [3, 5, 6, 10] (20 µmol/L lower than 
physiological saturation of urate). However, particularly in Britain, the target has 
shifted to 300 µmol/L [3, 5, 6] to ensure dissolution of MSU crystals and prevention 
of a recurrent attack. Despite treatment to target, serum urate concentration is not a 
powerful diagnostic tool – not all people with hyperuricemia develop gout, and 
surprisingly, not all those with gout are hyperuricemic. Renal excretion increases 
during an acute gout attack [3, 6, 9] [11], or perhaps specific physicochemical states 
of certain tissues can be an explanation [12]. 
1.1.2 Gout in NZ 
Although gout and hyperuricemia prevalence is increasing globally, NZ has especially 
alarming rates. Māori and Polynesian groups have the highest serum urate levels in 
the world and although some variation must lie in the environment, genetic heritage 
has to play a big role in these populations [13]. 
Prior to 1997, the most recent studies into NZ prevalence rates were in 1958-1966 
for Europeans/non-Māori and 1978 for Māori. These studies found gout was 
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prevalent in 4.5%-10.5% of Māori men, and up to 2% in Māori women [14]. 
Europeans/non-Māori men had a gout prevalence of 0.7%-2.0%, with no gout 
reported in women [14]. 
In 1997 [14] another measurement of prevalence was taken, and the results are 
presented in Table 1. A 2013 [15] study again looked at prevalence, and the results 
of that paper are presented alongside the results from 1997 in Table 1.1. 
TABLE 1.1 – Prevalence of hyperuricemia and gout in NZ (2007 & 
2013) 
Hyperuricemia 
Maori  European/Non-Maori  
Male Female All Male Female All 
Klemp et al., 
1997 
27.1 26.6  9.4 10.5  
Stamp et al., 
2013 




Male All Male All 
Klemp et al., 
1997 
13.9 6.4 5.8 2.9 
Stamp et al., 
2013 
 10.3  2.3 
All figures shown are in percentage units. 
As shown in the table, gout prevalence is increasing in Māori and has mostly 
remained stable in non-Māori. The results of the 2013 study were not segregated by 
sex and as such rates of gout in men cannot be compared across the studies, but 
looking at the overall increase from 6.4% to 10.3% in Māori supports the observation 
that gout is on the rise in the Māori population. Interestingly, hyperuricemia appears 
to be declining in both Māori and non-Māori populations and the 2013 paper offers 
some possible explanations, although the true reason is as yet unclear. Including 
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patients receiving ULT may have led to an underestimate of hyperuricemia, while the 
diagnosis of gout may have an inherent tendency to overestimate occurrences. In 
addition, perhaps also there is an earlier onset of mild hyperuricemia with greater 
longevity contributing to increasing gout prevalence [15]. Furthermore, it is important 
to note that the two studies had very different methods of classifying gout – the 1997 
paper used strict criteria, following the American Rheumatism Association (ARA) 
guidelines. The 2013 paper, on the other hand, included self-reported and GP-
reported diagnoses of gout, which are likely to have contributed in some way to an 
overestimation of gout. Both studies found that treatment of gout was inadequate, 
both in terms of drug prescription and education [14, 15]. 
1.1.3 Environmental factors 
In terms of environmental factors, both beer and spirits increase risk of 
hyperuricemia – however, wine does not. Red meat, seafood and fructose are also 
risk factors, but dairy and coffee (caffeinated and decaffeinated, interestingly) are 
protective of hyperuricemia [3, 4, 6, 9]. Oestrogen is uricosuric, which means that it 
increases excretion of urate from the body. This explains why women typically don’t 
suffer from gout until after menopause, although post-menopausal hormone 
therapies usually have a similar effect to oestrogen of reducing serum urate [3]. 
1.1.4 Genetic factors 
In 2009, one of the first major GWAS to investigate serum urate concentrations 
found 9 loci that were significantly associated: SLC2A9, ABCG2, SLC22A12, 
SLC17A1, SLC22A11, SLC16A9, GCKR, LRRC16A, and near PDZK1 [16]. Six of 
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these loci were confirmed in 2010 (SLC2A9, ABCG2, SLC17A1, SLC22A11, 
GCKR, and PDZK1) while two novel loci were identified in the same study 
(R3HDM2-INHBC region and RREB1) [13, 17]. Various studies in other 
populations have confirmed many of these loci across ethnic groups [1, 18, 19], while 
more recent GWAS have identified a multitude of novel loci [1, 2, 16]. 
The two major gout and urate risk loci are SLC2A9 and ABCG2 – genetic variants in 
SLC2A9 account for 3.5% of variation of serum urate in European Caucasians, 
which is very large considering the complexity of the trait [16]. This gene codes for a 
transporter that is likely to reabsorb urate in the primary tubule of the kidney [16]. 
There are multiple variants within the introns of SLC2A9 that are associated with 
serum urate (and gout). There is a need for identification of the true causal variant 
and which variants are simply being “associated” with the trait due to linkage 
disequilibrium with the causative variant [16]. There is also a subset of associated 
SNPs at this locus in Asian populations, demonstrating the need for fine-mapping to 
identify causal variants across ethnicities [16]. 
A single variant in ABCG2 accounts for 0.5% of variance in serum urate in 
Europeans, and also increases risk of gout in European, Chinese, Japanese and NZ 
Polynesian populations – interestingly, it does not increase risk in NZ Māori, which 
at this stage this has not been explained [16]. ABCG2 is expressed in intestinal 
epithelial cells and the apical membrane of the kidney proximal tubule and is 
responsible for secretion of uric acid [16]. This variant reduces secretion by 50%, an 
obvious mechanism for raising systemic serum urate concentrations [16]. 
! 8 
1.1.5 Gout and GWAS 
Gout is a common disease, and genetically complex. Unlike “simple” Mendelian 
disorders with one or two pathological alleles, gout is affected by many genes in 
different tissues, some of which may be protective against gout. A powerful tool for 
identifying these loci with small individual effects is a GWAS, which compares the 
genomes of cases and controls – typically with a massive sample size – to identify 
which SNPs are associated with a disease. Two recent papers have made a big impact 
on the field of gout genetics – Kottgen et al. (2013) and Okada et al. (2012). 
GWAS typically use hyperuricemia as their measured phenotype – this type of 
analysis will lose power very rapidly if the cases and controls are not strictly defined, 
as small effects can be easily lost on such a large scale. Serum urate can be simply 
and cheaply determined with a simple blood test, and most importantly it is objective. 
Diagnosis of gout can be subjective without definitive analysis of patient samples 
under a microscope, which is impractical for such large studies. Therefore, GWAS 
can be used to identify variants associated with hyperuricemia, which is necessary for 
the onset of a gout attack. Although it is not sufficient to cause gout, variants found in 
these analyses must be researched further, therefore a GWAS never claims to find 
gout variants immediately without thorough characterisation of the variants produced. 
Kottgen looked at data from 140,000 European individuals (and a significant number 
of individuals from African American, Indian, and Japanese populations) while 
Okada analysed 71,149 East Asian individuals. 18 new regions were associated with 
serum urate by Kottgen and only one was associated with uric acid by Okada (MAF), 
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as the aim of the Okada paper was to look for associations with kidney function-
related traits, not simply urate or gout. 
However, referring to MAF as being associated with serum urate is technically 
incorrect – the loci that have really been associated are a mass of SNPs upstream of 
MAF, in non-coding DNA. These SNPs fall into three groups: the first group is ~2 
kb upstream of the MAF promoter, while the second is ~60 kb upstream of the 
promoter. Both these groups were associated with serum urate in Okada’s study. In 
Kottgen’s, that second group was also associated, as was the third group, which is 
~300 kb upstream of the promoter. Figures 1.1 and 1.2 show the results of these 
studies and how the groups are formed. Figure 1.3 demonstrates the relative position 
of each group on chromosome 16 with regards to the MAF promoter, and Table 1.2 




FIGURE 1.1 -  LocusZoom showing the results of Okada et al .  2012. This 
graph shows the SNPs analysed in this paper plotted according to genome position and –log 
P value (significance threshold of 5 is demonstrated by the dashed line). The purple SNP is 
the most significant SNP in the Kottgen study (to allow comparison with Figure 1.2 below), 
and the red, green and blue SNPs are in projected linkage disequilibrium (LD) with that 
SNP (colours relates to degree of LD). Just the results of SNPs around MAF are represented 
here. 
!
FIGURE 1.2 -  LocusZoom showing the results of Kottgen et al .  2013. 
This graph shows the SNPs analysed in this paper plotted according to genome position and  
–log P value (significance threshold of 5 is demonstrated by the dashed line). The purple 
SNP is the most significant, and the red, orange, green and blue SNPs are in projected 
linkage disequilibrium (LD) with that SNP (colours relates to degree of LD). Just the results 
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Table 1.2 -  Chromosome locations of MAF  and upstream regions of 
interest  
Feature Location on chromosome 16 (region 
included in this study): hg19 assembly 
MAF gene 79,627,745-79,634,622 
Region 1 (~2 kb) 79,634,622-79,646,999 
Region 2 (~60 kb) 79,695,939-79,757,197 
Region 3 (~300 kb) 79,923,857-79,943,562 
 
1.1.6 Limitations of a GWAS analysis 
The problem with a GWAS analysis is in the name – it only identifies associations, 
and it is important to remember when reading these papers that correlation does not 
equal causation. Much has been made in recent years of these types of studies, and it 
is true that they are powerful tools. However, care must be taken to make the 
distinction between an associated variant and a causal variant – and the results of 




! ! !! !
~60 kb ~300 kb ~2 kb  
MAF 
5’ 3’ 
FIGURE 1.3: Schematic diagram of MAF  (chr16) and the general location 
of three upstream groups of genetic variants associated with serum urate.  
The two regions closest to the MAF promoter were identified in Okada et al. 2012,  
while the two regions furthest upstream were identified in Kottgen et al. 2013 (The 
middle region was identified by both studies.) 
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has been associated. Really, GWAS is excellent at supplying candidate variants that 
have an association with a disease, and then these candidates must be investigated 
before any conclusions can be drawn. Moreover, variants are often identified in non-
coding regions of DNA, where it is impossible to accurately predict the function of a 
variant without careful investigation. 
1.2 GENE REGULATION 
1.2.1 DNA in three dimensions 
Despite conventional diagrams that promote DNA as a linear molecule, the reality is 
that in three dimensions, DNA (known as chromatin when it is in its packaged form 
in the nucleus of a cell) forms specific loops and coils. This not only allows roughly 2 
meters of the molecule to condense almost 10 000-fold, but also allows for 
interactions between seemingly distant parts of the genome [20] [21, 22]. Theories of 
cis-regulation allow us to consider how a locus up to 300 kb from a gene may 
somehow be regulating that gene, as in the case of MAF. The key question to arise 
from the GWAS analyses discussed above is how non-coding DNA can influence 
serum urate concentrate, and the key to the answer lies in the 3D arrangement of 
chromatin. 
Chromatin is made up of repeating units of nucleosomes, which consist of 147 base 
pairs of DNA wrapped around eight histones (small, highly basic proteins) [20, 21, 
23]. So DNA is wrapped around histones (forming a nucleosome) which then pack 
together tightly in the cell. To access this DNA, the histones are modified to “open” 
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the chromatin to allow polymerase (among other molecules) to bind [21]. Whether 
chromatin is “open” or “closed” at a specific gene determines which genes are active 
in a cell, and so gives rise to differentiation between cell types [21, 24]. Chromatin is 
then looped in the nucleus in such a way that even two apparently remote DNA 
regions may in reality be found alongside each other (Figure 1.2). 
 
 
1.2.2 Regulatory elements 
Distant DNA regions can have an effect on each other due to 3D chromatin looping, 
but the type of interaction they have is determined by the genetic signatures at the 
region.  Common markers can be found throughout the genome and particular 
signatures are known to have specific functions; typically, these signatures act as 
enhancers or insulators. 
Enhancers interact with a promoter to amplify expression of a gene through 




FIGURE 1.4: Schematic diagram demonstrating how a possible 3D DNA 
loop can bring non-adjacent DNA regions into proximity. Despite 300 kb 
of DNA intereceding the MAF promoter and the furthest SNP group, if it forms a 
loop such as the one in the diagram, any regulatory elements contained in that region 
will be brought into proximity with the MAF promoter. If a SNP resides in this 
element and alters its function, regulation of MAF will be altered and could be 
causing an association with serum urate to be detected. 
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transcriptional co-factors [25, 26]. Common signatures of enhancers include histone 
modifications, specifically H3K4me1, H3K4me2 and H3 acetylation [25, 27, 28]. It 
is thought that the H3K27ac distinguishes active enhancers from those that may be 
“poised”, or currently inactive enhancers [29]. 
Insulators prevent genes from being expressed, typically through a remodelling of the 
chromatin or by physically blocking transcriptional molecules from binding to the 
DNA, or through excluding an enhancer from acting at a promoter [30]. Proteins 
that commonly bind to insulator sites are CCCTC binding factor (CTCF) and 
cohesin [26]. CTCF, an 11-zinc finger protein [27], binds specifically to CCCTC 
motifs in DNA, while other proteins bind to CTCF to participate in insulator 
function. One such protein is cohesin, a ubiquitous protein that acts to bind 
chromatin together [26]. Together, CTCF and cohesin work to spatially exclude an 
enhancer from a promoter, regulating activity at such a promoter through negative 
regulation of an enhancer [31, 32]. 
Finally, DNase hypersensitivity (DHS) sites in DNA are a sign that the DNA region 
in question is in open chromatin – if a site is highly sensitive to DNase (an enzyme 
that degrades DNA), then it must be accessible and therefore cannot be in closed, 
tight chromatin [24, 33]. This indicates that the region is active, and if it is non-coding 




The MAF gene encodes a transcription factor [34], and contains a leucine zipper 
motif resembling that of other DNA binding proteins [35]. MAF transcription factors 
form a special sub-class of the basic-leucine zipper transcription factors and have a 
variety of roles in a variety of tissues, particularly in differentiation regulation [36], 
including in the lens, kidneys, liver, T cells and nervous system [37]. MAF has been 
mapped to human chromosome 16q23.2 [38]. 
Much of the research into MAF function refers to its role in immune differentiation, 
particularly of T-helper-2 (Th2) cells. MAF is also involved in development of Th17 
cells, and regulating interleukin-4 (IL-4) transcription in CD4-positive follicular 
helper cells [34]. In mice, Maf has been shown to enhance the promoter of Il23r, 
exhibiting a regulatory effect [39]. 
Minimal change nephrotic syndrome (MCNS) is a disease of the kidney – 
specifically, the glomerulus, the initial filter in the kidney – in which MAF is believed 
to play a role. In 1974 it was hypothesised that atypical T cell activation led to MCNS 
[40], and in 2002 it was shown that MAF (among other immune genes) was 
differentially regulated in MCNS [41]. Maf is expressed in the renal proximal tubules 
of mice on embryonic day 16 until 4 weeks after birth [37], with this expression 
pattern confirmed in zebrafish [42]. 
! 16 
Homozygous Maf knockout mice have flawed lens development and eyes that fail to 
grow to full size [43]. Another study has shown a shortened head and confirmed the 
defective lens development phenotype, while commenting that almost all the mice 
die after only a few hours postpartum [44]. 
Recently, a study has been published announcing the characterisation of a disorder 
with defects in many developmental programmes [45]. The genetic abnormality 
giving rise to this disorder is a “narrow spectrum” of amino acid substitutions in 
MAF, and phenotype characteristics include lens and eye defects as well as 
“sensorineural deafness, intellectual disability, seizures, brachycephaly, distinctive flat 
facial appearance, skeletal anomalies, mammary gland hypoplasia, and reduced 
growth”, suggesting that MAF plays a role in many developmental pathways. 
With regards to this study, there are two important tissues in which MAF expression 
is likely to be most relevant – the kidney and immune cells. Previously identified 
serum urate-relevant genes are solute transporters in the kidney, and MAF 
expression in the developing kidney may play a role in setting up the organ’s ability to 
excrete serum urate. However, MAF also has a role in immune cell differentiation, 
and gout is an inflammatory disease. It is possible there is a link between serum urate 
and the immune system that has as yet not been described. Therefore, it is important 
to discover the causal variant upstream of MAF, identify if it is regulating MAF, and 
in which tissues the casual variant is expressed. This would allow us to determine the 
pathway of action and possibly a novel factor in serum urate control. 
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1.4 AIMS & OBJECTIVES 
The aims of my study are as follows: 
1) To identify a causal variant from the SNP region upstream of MAF. The literature 
currently shows a correlation between this general non-coding area and serum urate, 
but without solid functional data it is impossible to prove causation.  
2) To test the hypothesis that one or more of these associated SNPs lies within a 
regulatory element, and that the variant SNP alters the function of this regulatory 
element.  
3) To determine if identified regulatory elements interact long-range with the MAF 
gene. This would reveal the potential of SNPs in regulatory elements that contact the 
MAF gene to alter gene regulation, possibly leading to atypical serum urate levels. 
With this in mind, this study encompasses three main objectives: 1) in silico analysis 
to identify candidate causal variants from this region; 2) determine the function of a 
previously identified regulatory element within the SNP region; 3) investigate the 
three-dimensional arrangement of chromosome 16, focusing on the MAF promoter 




All chemicals, consumables, solutions and buffers used in this study are listed in 
Appendix I. 
2.1 BIOINFORMATICS 
An in silico analysis was carried out to identify significantly conserved SNPs 
associated with serum urate levels across populations captured in publicly available 
datasets.  
2.1.1 Publicly available datasets 
The four studies used in the analysis (ARIC, CHS, CARDIA and Framingham) are 
all from the United States and have provided their data online to be accessed with 
authorisation. They have a similar purpose: investigation into an aspect of 
cardiovascular health. Advances in genetic technology meant that these studies began 
to explore genetic factors in addition to their original aims. Studies that collected 
genotype and serum urate data were included in this analysis, in order to discern an 
association between the two. Listed below are the four data sets used in this analysis. 
2.1.1.1 Atherosclerosis Risk in Communities (ARIC) 
Designed to investigate the cause and course of atherosclerosis, ARIC was 
established in 1987 by recruiting a total of 15,792 individuals across four field centres 
in the US [46]. These participants were extensively examined with medical, social 
and demographic data all being collected. Five visits were conducted between the first 
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in 1987 and the final in 2011-13, with yearly telephone follow-up. The study is 
funded by the National Heart, Lung and Blood Institute (NHLBI) and investigates 
variation in cardiovascular risk factors by race, gender, location and date, as well as 
records the occurrence of hospitalised myocardial infarction and coronary heart 
disease deaths between the ages of 35 and 84 years. 
2.1.1.2 Cardiovascular Health Study (CHS) 
The purpose of CHS is to study risk factors for coronary heart disease and stroke in 
people aged 65 years and over [47]. Also funded by the NHLBI and beginning in 
1988, the study recruited 5,201 individuals from four US communities before 
recruiting another, predominantly African-American cohort of 687 people in 1992.  
Participants were subject to thorough medical examinations yearly, from inclusion in 
the study until 1999. 
2.1.1.3 Coronary Artery Risk Development in Young Adults (CARDIA) 
Another study funded by the NHLBI, CARDIA was initiated in 1985 with the 
recruitment of 5,115 healthy individuals aged between 18 and 30 in order to study 
the aetiology of cardiovascular disease from young adulthood [48]. The cohort was 
enrolled across four field centres in the US and comprised of approximately equal-
sized subgroups (age, sex, race and level of education). Follow-up examinations 
occurred at Year 2, Year 5, Year 7, Year 10, Year 15, Year 20 and Year 25, with 
additional regular contact to maintain records of hospitalisation and outpatient 
procedures. These examinations included both medical and social data as well as 
family history, lifestyle factors and behavioural variables.  
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2.1.1.4 Framingham Heart Study 
The longest-running study included in this analysis, the Framingham Heart Study 
began in 1948 as a result of steadily rising mortality rates from cardiovascular disease 
(CVD) in the US [49]. The study aimed to identify common factors involved in the 
development of CVD by recruiting 5,209 healthy individuals between 30 and 62 
years of age in the town of Framingham, Massachusetts and looking for patterns 
associated with CVD. Two-yearly examinations included physical and lifestyle data 
being collected, as well as laboratory tests. In 1971, 5,124 of the original cohort’s 
adult children and their spouses were recruited as the second generation of the study, 
followed up with the third generation in 2002, comprising of 4,095 grandchildren of 
the first generation. Run in conjunction with Boston University, the NHLBI funds 
the Framingham study, the third generation of which was used for the in silico 
analysis aspect of this project. 
2.1.2 Subject lists 
Subsets of the original cohort, known as subject lists, were created by Ruth Topless of 
the Merriman lab group (University of Otago) in order to ensure that the analysis 
included only participants relevant to our study – as the original aims of these big 
studies were predominantly related to cardiovascular health, using this data in an 
analysis of serum urate means not all participants will be appropriate. Inclusion and 
exclusion criteria for these subject lists can be found in Table 2.1. 
!  
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TABLE 2.1 -  Criteria for subject l ists to transform publicly available 
data 
Inclusion criteria Effect of included criterion 
Ethnicity data Ancestral differences between different 
ethnic groups can dampen or flatten any 
detectable association due to possible 
opposite average effects of the same 
SNP. Composing different subject lists 
for Caucasian and African-American 
participants helps to avoid this. 
Genotype SNP data must be available for every 
participant included in this analysis for an 
association to be made. 
Phenotype Urate data is required for every included 
participant – absence of this information 
is equivalent to not being phenotyped for 
the purpose of this analysis. 
!
Exclusion criteria Effect of excluded criterion 
Gout Serum urate is the phenotype used to 
detect an association, as it is simply and 
objectively measured. Presentation of 
gout can confound this phenotype as 
individuals with gout are likely taking 
urate-lowering therapy (ULT), artificially 
altering their serum urate levels.  
Kidney disease Altered kidney function will have an 
unknown effect on urate levels, and as 
such only participants without kidney 
disease are included to avoid 
misclassification of phenotype. 
Taking ULT Any medication prescribed to artificially 
lower urate levels would produce a 
misleading association between genotype 
and urate in this analysis and as such 
participants are included provided they 
are not using ULT. 
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Exclusion criteria Effect of excluded criterion 
Taking diuretics Diuretics increase urate reabsorption in 
the kidney and decrease excretion, 
leading to artificially elevated serum urate 
levels. Again, this would produce a 
misleading association and cannot be 
included in the analysis. 
Constructing subject lists for use in this study restricts the number of participants 
available for analysis. As such, final participant numbers were as shown in Table 2.2. 
TABLE 2.2 -  Participant numbers included in subject l ists 
 Caucasian African-American Total 
ARIC 7,467 1,909 9,376 
CARDIA 1,618 1,387 3,005 
CHS 2,424 368 2,792 
Framingham 3,330 – 3,330 
Total 14,839 3,664 18,503 
 
2.1.3 Regression analysis (PLINK) 
PLINK is a toolset developed by Shaun Purcell at the Center for Human Genetic 
Research, Massachusetts General Hospital, in conjunction with the Broad Institute of 
Harvard and MIT [50]. In this analysis PLINK v1.07 was used to build a regression 
model of serum urate association with genotype. 
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A regression analysis uses statistics to estimate the relationship between variables – in 
this case, genotype and serum urate level (Figure 2.1).  
If a site in the genome is associated with a change in serum urate levels, a relationship 
such as the one shown above may occur. This shows each participant, represented as 
dots on the graph, at the location where their measured serum urate level and 
genotype meet. In this case, it appears that the homozygous A1 genotype is 
associated with an elevated serum urate level when compared to the homozygous A2 
genotype, and the regression model fits this trend accordingly. 
PLINK generates regression models according to the input data and produces 
statistical information which is then utilised in downstream applications. 
In this analysis, the constructed subject lists were subjected to a PLINK quantitative 
trait analysis. Each subject list was run individually, and each dataset had its own set 
FIGURE 2.5 -  Schematic diagram illustrating how a regression model is  
constructed across genotypes. Participants are plotted according to their 
genotype at a locus (A1 homozygous, A2 homozygous or heterozygous) and 
measured serum urate level, and a regression analysis builds a model based on a line 





























of subject lists. Table 2.3 details the commands given to PLINK in order to produce 
the required regression analysis. 
TABLE 2.3 -  List  of instructions given to PLINK to produce regression 
analysis of genotype and serum urate 
Command  Result of command 
Inside the appropriate dataset, within 
the ‘Analysis’ menu, ‘GWAS’ was 
selected, followed by ‘PLINK 
quantitative trait association’. 
 Each analysis is performed in the 
individual dataset, and PLINK is 
instructed to perform the correct 
regression analysis. 
Subject section expanded, and subject 
list imported. 
 This instructs the analysis to be 
performed in only the participants 
contained in the subject list. The 
analysis must be repeated for every 
subject list in every dataset. 
Correct phenotype dataset selected, 
and URICACID (or correct variant 
thereof) selected. 
 This instructs the regression analysis to 
be performed – i.e. which trait is to be 
measured in relation to genotype. 
Covariates entered (if performing an 
adjusted regression analysis). Covariates 
selected are: Gender, BMI01 (BMI), 
V1AGE21 (Age), PCA1, PCA2. 
 These covariates adjust the data for 
known factors that influence 
presentation of gout. Sex, age and BMI 
are factors known to affect risk of gout, 
while PCA1 and PCA2 considers the 
effect of a principal component 
analysis1. 
‘Use marker map’: NCBI dbSNP build 
135 (Nov 2011, hg37.3). 
 This map ties the genotype information 
to the genome. 
   
   
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!!!!!!
1!A principal component analysis considers the differences within a set of data. The 
first principal component (PCA1, in PLINK) accounts for the most variation in a set, 
while the second accounts for the next largest level of variation, and so on. By 
adjusting for PCA1 and PCA2, differences that may affect the analysis are minimised, 
allowing possible unknown confounding factors to have a reduced impact.!
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Command  Result of command 
‘Split analysis by chromosomes’ was 
selected, using chromosome 16. An 
annotation map was created and 
uploaded, and only markers present in 
this map were included. The map was 
created from dbSNP build 135 as 
above, covering the region of 78 Mb to 
81 Mb of chromosome 16. This region 
contains 88,000 SNPs. 
 This allows the analysis to be restricted 
to only a region of interest – in this 
case, the regression analysis will only be 
performed on SNPs within the MAF 
region, widely defined as the 3 Mb 
region around the MAF gene. Of the 
88,000 SNPs present, an analysis can 
still only be produced with SNPs 
present in the dataset used. 
Filtering includes minor allele 
frequency (MAF) greater than 0.01, 
max MAF less than 0.5, and missing 
genotype rate less than 0.1. 
 Any SNPs with a MAF less than 1% 
will be ignored (these are very rare 
alleles), as will SNPs with a MAF over 
50%. A missing genotype rate of 0.1 
means that a participant will be 
included as long as they are at least 
90% genotyped – some missing SNP 
data is acceptable, but participants with 
over 10% missing data are excluded. 
Linear regression is selected as the test 
type. 
  
All other options remain as default.   
 
The output file is downloaded and ‘cleaned up’ – meaning all extraneous columns 
are deleted from the resultant Excel file, except for: Marker (this is the SNP rs 
number), Chr (chromosome – all = 16), BP (base position in the genome), A1 (effect 
allele), Test (only present in adjusted regression models), NMISS (sample size), Beta 
(difference between genotypes – e.g. if Beta = 0.02, then the difference between 
genotype AA and AB will be +0.02, and the difference between AB and BB will 
again be +0.02), SE (standard error) and P (P value). 
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2.1.4 Preparation for meta-analysis 
Each text file was uploaded to RStudio v0.98b [51] and all datasets merged into one 
according to SNPs; the SNP column contained the information used to align the 
datasets. This produced two files – one containing all the data from the combined 
datasets and adjusted for the aforementioned covariates, while the other was identical 
but unadjusted. 
These files then required adjusting prior to further analysis – each original study had 
not genotyped participants in necessarily the same way, and as such not every SNP 
was present in every dataset. Missing data had to be removed from the spread sheet 
so as not to produce errors during meta-analysis. Further, at each SNP (5469 in 
total), care had to be taken to ensure that the same allele was being considered the 
effect allele in every dataset. If not, the allele needed to be switched to keep 
consistency between datasets and the Beta score multiplied by -1.0 to change the 
direction of the effect. 
Once the spread sheet was appropriately configured, each individual dataset needed 
to be removed to a separate spread sheet to upload for meta-analysis. 
2.1.5 Meta-analysis (Metal) 
In the uploaded dataset folder (one adjusted, one unadjusted), under the ‘Analysis’ 
group, ‘Genome browser’ was selected, followed by Metal meta-analysis [52]. Within 
this input page, all defaults remained except the MAF 78-81 Mb map was again 
applied, and analysis was restricted to chromosome 16. 
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2.1.6 LocusZoom 
Once the meta-analysis was completed, the file could be downloaded and converted 
to a text file with Unix encoding using TextWrangler 5.0. This file was then uploaded 
to LocusZoom [53], an online tool available for plotting and visualising genome-wide 
meta-analysis results. 
2.2 CELL CULTURE & MAINTENANCE OF CELL LINES 
2.2.1 Cell lines used in this project 
Cell lines were stored in a Thermo Scientific liquid nitrogen dewar. All cell lines 
(Table 2.3) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) + 10% 
fetal bovine serum (FBS), and maintained at 37 °C in a humidified incubator with 5% 
CO2. 
Table 2.4 -  Cell  l ines used in this project 
Cell line Cell type Source Reference 
HEK293 Human embryonic kidney Braithwaite lab [54] 
HeLa Human epithelial cancer Braithwaite lab [55] 




2.2.2 Reviving cells from liquid nitrogen stocks 
Cells were transferred from liquid nitrogen dewar to a 37 °C waterbath for rapid 
thawing. The thawed cell suspension was added to 10 ml of pre-warmed media in a 
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50 ml Falcon tube following which the cells were pelleted by centrifugation at 250 g 
for 5 minutes. Supernatant was aspirated and cells were resuspended in 25 ml of 
fresh media and seeded in a medium flask. 
2.2.3 Splitting cells for new passage 
Once the cells had formed a monolayer and reached 80-90% confluence they were 
split for a new passage. The media was carefully aspirated and the adherent cells were 
washed with 15 ml of pre-warmed phosphate-buffered saline (PBS). 5 ml of 0.5% 
trypsin was added to the cells evenly and incubated at 37 °C for 2-3 minutes. 15 ml of 
pre-warmed media was added to the flask to inactivate the trypsin and for 
resuspension of the cells. Cells were subcultured at the ratios of 1:3 and 1:5 as 
required. 
2.3 MAF EXPRESSION ANALYSIS 
2.3.1 Primer design 
Three sets of primers designed to amplify expressed MAF were used in this project – 
two from published manuscripts and the third was custom designed. As there are two 
transcriptional variants of MAF (OMIM 177075), the first set was designed to amplify 
both [57], while the second amplified only the short variant [58]. 
The third pair was designed using National Center for Biotechnology Information 
(NCBI) PrimerBLAST [59]. Primers were designed to span an exon-exon junction 
as a secondary exclusion step to avoid amplification of genomic DNA in the final 
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quantitative PCR (qPCR). Only primers for transcript variant 1 (short) could be 
obtained. The list of primer sequences is available in Appendix II. 
2.3.2 RNA extraction 
RNA was extracted from 106 HEK293, HeLa and MCF7 cells, and 5x105 MCF10A 
cells. Cells were lysed using lysis buffer and RNA was extracted according to 
manufacturer’s guidelines. RNA was quantified using a Nanodrop® ND-1000 v3.81 
spectrophotometer. 1 µl of the sample was applied to the stage of the apparatus, 
which then measured the concentration and purity of the nucleic acids via 
absorbance of UV-visible light. RNA was stored at -80 °C until required. 
2.3.3 cDNA synthesis 
Complementary DNA (cDNA) was synthesised from MAF RNA using qScript - 4 µl 
of qScript™ cDNA SuperMix, 500 ng of total RNA and RNase-free H2O were used 
in a 20µl reverse-transcription reaction. This was performed in an Applied Biosystem 
Thermal Cycler 2.08 at 25 °C (5 minutes), 42 °C (30 minutes) and 85 °C (5 minutes), 
with the final product being stored at -20 °C until required. 
2.3.4 qPCR and analysis 
To measure relative expression of MAF in HEK293 and HeLa cells, the first two 
primer pairs (from published papers) were used in a qPCR experiment with cDNA 
synthesised from these cell lines. The cDNA was diluted 1:5 to produce a final 
concentration of 100 ng/µl. This technique uses real-time PCR. Following 
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optimisation, a second expression analysis was carried out using newly designed 
primers and cDNA synthesised from HEK293 and MCF10A cells. 
Relative MAF expression was normalised to three reference genes – RPL13A, 
GAPDH and CYCLOPHILIN. These primers were previously validated in the lab 
by an external standard curve and primer efficiencies fell into the expected range of 
80-100%. 
The qPCR mix was made for each primer set in each cell line, as outlined in Table 
2.5. 
TABLE 2.5 -  qPCR reaction mix 
Reagent Amount per 20 µl (reaction volume) 
cDNA (500 ng) 1 µl 
Forward primer (3 µM) 1 µl 
Reverse primer (3 µM) 1 µl 
SYBR® Green (2x) 10 µl 
MilliQ H2O 7 µl 
 
The qPCR was performed using Roche LightCycler® 480 II using the following 
programme: 95 °C for 30 seconds, followed by 40 cycles of 95 °C for 5 seconds and 
60 °C for 30 seconds. Melting curves were produced in one cycle of 95 °C for 5 
seconds, 60 °C for 60 seconds and then continuous 95 °C. 
Analysis was carried out using Biogazelle qBase+ software. 
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2.4 LUCIFERASE ASSAY 
2.4.1 Plasmid and reporter constructs 
Reporter constructs were used in this study to investigate the regulatory capability of 
elements upstream of the MAF gene, and are outlined in Table 2.6. 
PCR®8/GW/TOPO (TOPO) vectors containing the elements of interest were 
already available as they had been previously cloned [42]. 
Gateway cloning was utilised in this study (as opposed to traditional enzyme-based 
cloning), whereby inserts can be transferred between plasmids via site-specific 
recombination [60]. The entry vector, TOPO (Figure 2.3A), contains attL sites and is 
used to transmit the insert to destination vectors; in this case, pGL4.23-GW (Figure 
2.3B). The destination vector contains attR sites (attL and attR sites are the sites 
required for the LR recombination reaction) and the ccdB gene. ccdB acts as a 
negative control for the recombination – post-recombination the gene is lost, so any 
non-recombinants will retain the toxic gene and be incapable of survival. 
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FIGURE 2.2 -  Maps of plasmids used in this study. A) 
PCR™8/GW/TOPO® plasmid was used as an entry vector for insertion of potential 
regulatory fragments into B) pGL4.23-GW, the plasmid used to perform the 
luciferase assay. Gateway sites allow simple recombination between the two plasmids, 




















2.4.2 Gateway cloning 
Homologous recombination is utilised in the LR recombination reaction, allowing 
the putative regulatory elements contained in the TOPO vector to be inserted into 
the pGL4.23-GW vector using a simple protocol. The LR recombination reaction 
was carried out according to Life Technologies protocol using Gateway LR clonase II 
enzyme mix. 
Table 2.7 -  Gateway cloning reagents 
Reagent Amount (µl) 
Entry vector (TOPO) with putative 
regulatory elements 
1 µl (150 ng) 
Destination vector (pGL4.23-GW) 1 µl (150 ng) 
LR clonase II enzyme mix (5x) 1 µl 
Milli-Q H2O 2 µl 
 
Reagents in Table 2.7 were added to a 0.2 ml tube and incubated at 25 °C for 1 hour. 
0.5 µl of proteinase K was then added before further incubation at 37 °C for 10 
minutes – this step inhibits further enzyme activity. 
TOPO vectors containing LacZ were used as a positive recombination control, while 
1 µl of Milli-Q H2O replaced the TOPO vector in the negative control. 
!  
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2.4.3 Transformation of plasmids in competent cells 
pGL4.23-GW stocks were originally propagated in One-shot ccdB survival cells. 
Recombination products from section 2.4.2 were transformed into competent 
Escherichia coli cells (one-shot TOP10 and Stratagene XL1 Blue). pUC19 was used 
as a positive transformation control [62], and the negative recombination control 
remains a control for transformation. 
2 µl plasmid DNA (1 µl of pUC19) was added to a vial of E. coli competent cells, 
mixed gently and incubated on ice for 30 minutes. Samples were transferred to a 42 
°C waterbath for 45 seconds and quickly transferred back to ice for 2 minutes. 500 µl 
of pre-warmed Luria-Bertani broth (LB) [63] was added to the cells and incubated, 
shaking (200 rpm), for 1 hour at 37 °C. Following incubation, cells were centrifuged 
at 3000 rpm for 10 minutes and majority of the supernatant was discarded. Pellet was 
gently resuspended and ~150 µl of cell suspension was plated onto LB agar plates 
containing 100 µg/ml ampicillin and incubated overnight at 37 °C. Plates for the LacZ 
control contained 50 µl of 20 µg/ml X-gal [64]. 
Following overnight incubation, three successful transformation colonies from each 
plate were picked using fresh pipette tips and incubated overnight at 37 °C with 
shaking (200 rpm) in 4 ml LB, 100 µg/ml ampicillin. 
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2.4.4 Plasmid preparation 
The bacterial culture was centrifuged at 13,300 rpm for 1 minute and the supernatant 
discarded. Plasmids were then extracted from cells using the Macherey-Nagel mini-
prep kit according to the kit protocol, and DNA was stored at -20 °C until required. 
2.4.5 Sequencing 
To confirm that the clones were successful product – i.e. the putative regulatory 
elements had correctly recombined into the pGL4.23-GW plasmid – the extracted 
plasmids were sent for sequencing using primers specific to the Gateway sequence. 
Sequencing was carried out by Genetic Analysis Services, University of Otago, using 
BigDye® Terminator Version 3.1 Ready Reaction Cycle Sequencing Kit. 
2.4.6 Transfection 
To determine the most efficient method of transfection, cells were both forward and 
reverse transfected with pGL4.23-GW+putative regulatory elements. Forward 
(traditional) transfection was used to complete biological replicates of the assay as it 
was found to produce the best results. Cell densities of 2.5x104, 1x104, and 8x103 
were tested, with 8x103 cells per well found to be at the correct confluence (~50%) at 
time of transfection. 
With reverse transfection, the cell suspension is added onto pre-plated transfection 
complexes. Cells are then incubated at 37 °C for 48 hours. This reduces the protocol 
by a day, as no wait is required for the cells to adhere. 
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In forward transfection, the cells are seeded in each well. After 24 hours the 
transfection complexes are applied to the media and incubated at 37 °C for 48 hours. 
A transfection control, Renilla, was co-transfected with the pGL4.23-GW constructs 
– Renilla luciferase is evolutionarily distinct to the firefly luciferase within pGL4.23-
GW and as such can be differentiated during transfection analysis and allows for 
normalization for transfection efficiency [65]. 
TABLE 2.8 -  Transfection components per well  
 Component Amount (/well) 
 HEK293 cells 8x103 cells 
Lipofectamine® 3000 dilution Opti-MEM® Media 5 µl 
 Lipofectamine® 3000 Reagent 0.2 µl 
Master Mix Opti-MEM® Media 5 µl 
 Plasmid DNA 100 ng 
 P3000 Reagent™ 0.2 µl 
 Renilla luciferase construct 20 ng 
 
2.4.7 Transfection analysis 
If any of the putative regulatory elements within pGL4.23-GW have enhancer 
activity, then there should be an increase in luciferase expression. Elevated 
luminescence due to the increased luciferase activity can be detected using a 
luminometer. The Dual-Glo® Luciferase Assay System was used according to 
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manufacturer’s instructions. The Dual-Glo® Luciferase Reagent was diluted 1 in 4 in 
Milli-Q H2O and 40 µl of the diluted reagent was added to each well. The plate was 
shaken at 200 rpm for 10 minutes to thoroughly mix the cells before firefly 
luminescence was measured using a Victor™ X3 plate reader. 40 µl of Dual-Glo® 
Stop-and-Glo Reagent (also diluted 1 in 4 with Milli-Q H2O) was then added to the 
cells and mixed well, shaking at 200 rpm for 12 minutes. Renilla luminescence was 
then measured in the same plate reader. 
2.5 CHROMOSOME CONFORMATION CAPTURE (3C) 
2.5.1 Target selection 
The main targets of this study are F1 and F2 (Fig 2.4), the two putative regulatory 
elements identified in previous research. The purpose of performing 3C is to 
determine if these elements interact with the MAF promoter. The most upstream 
end of the MAF promoter region was used as the anchor, or bait region. 
In a 3C, background ligation can be picked up as a signal in the final qPCR analysis, 
and this ligation is more likely to occur with pieces of DNA that are in close 
proximity in the cell (i.e. adjacent sequences). As such, targets must be designed 
along the intervening DNA, between the bait and F1/F2, so that any peaks at these 
fragments can be read within context. This allows an understanding of how this 
region is organised to inform future analysis. 
There are three main regions directly upstream of MAF, between 60 and 300 kb 
away (the final region 300 kb upstream contains F1 and F2). Therefore, one target 
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was selected in region 1 (far enough from the MAF promoter so as to be distinct, but 
not outside the region). Two targets were selected in region 2, one at each end. Four 
targets were chosen in region 3 – the two putative regulatory elements and two 
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FIGURE 2.3 -  Out line of 3C targets and points of  interest. This diagrams 
show the position of the seven 3C targets in relation to the MAF promoter at the far 
left. The seven targets are divided among three regions – region 1 contains one target, 
approximately 8 kb from the MAF promoter. Region 2, approximately 60 kb from 
MAF, contains two targets while region 3 is approximately 300 kb from MAF and 
contains four targets. Two of these targets are denoted F1 and F2 (for fragment 1 and 
fragment 2, respectively). These fragments are the putative regulatory elements, and 
the features nominating them as such are shown on the diagram. 
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2.5.2 Enzyme selection 
Restriction enzyme choice is an important part of 3C design. Geneious R8 [66] was 
used to visualise restriction enzyme sites across the bait and targets. A 3C enzyme 
needs to be able to cut at CpG islands (as methylation is a regulatory signature and 
this project focuses on regulatory elements of a gene). The enzyme also needs to 
target a site of 4 base pairs, known as a “4-cutter”; this allows digestion at a reasonable 
frequency to resolve the two fragments of interest, as well as providing a thorough 
digestion along the intermediary targets. 
The initial search was limited to enzymes that met these criteria and were already 
readily available. MspI fit these requirements and was selected as the enzyme for this 
study. 
2.5.3 Primer design 
Two sets of primers are required at every target, as well as at the bait (in this case, the 
MAF promoter). A pair of primers to isolate the targets in the production of standard 
curves (control primers), as well as the final primers for use in the 3C-qPCR are 
required. 
Online software Primer3web v4.0 [67] was used to design primers once the targets 
were selected. Figure 2.4 shows where primers were placed around the restriction 
digest site. 3C primers were designed first, followed by “control” primers that sit 




FIGURE 2.3 -  Primer design: placement and size of amplicons. Part A of 
the figure shows primer placement at the bait region – the primers in green are the 
control primers (300 bp amplicon), the purple primer is the 3C primer (90 bp from 
the MspI site) and the Taqman probe is depicted in blue.  Part B depicts primer 
placement at each target, the red primers being the control primers (150 bp 
amplicon) and the orange primer being the 3C primer (the reverse primer to 
complement the forward primer at the bait). At the target, the 3C primer is 60 bp 
from the MspI site to produce a 150 bp amplicon when both 3C primers are used in 
conjunction. 
 
The best primers for each target (after taking into account limitations of product size) 
were selected based on Primer3 output and the criteria shown in Table 2.9. The 
Taqman probe was also designed using Primer3. 
Bait control primer 





Target control primer 























TABLE 2.9 -  Primer design features and parameters 
Feature Parameters 
Melting temperature (TM) 65-70 °C 
Length At least 18 nt, standard being 21 
Stability of final bases (3’ end) Aimed to be adenosine or cytosine – 
increased stability for specificity 
 Internal hairpins avoided 
 Self-complementarity avoided (e.g. 
GATC sequence) 
 Long sequences of a single base avoided 
Primer3 specific outputs GC content 50-60% 
 3’th <3.00 
 Hairpin <3.00 
 
2.5.4 Standard curve construction 
Standard curves are constructed to calculate primer efficiencies, and also so that 
original DNA concentration can be determined. Primers typically have different 
efficiencies (i.e. produce varied amounts of DNA product from the same starting 
concentration) and as such it is not a simple case of comparing CP values in the final 
3C-qPCR analysis – the DNA concentrations must be quantified, and as such 
standard curves are required. 
Producing standard curves for 3C is complex, as it requires artificial structures to be 
created prior to the serial dilutions and qPCR. These artificial constructs are 
conjugations of the bait and each target as might be expected to occur in the native 
nucleus. 
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2.5.4.1 Genomic DNA extraction 
As the 3C was to be carried out in HEK293 cells, so too the standard curves were 
generated from HEK293 genomic DNA. A large flask of fully confluent HEK293 
cells was trypsinised and washed with PBS. Cells were resuspended in 1 ml lysis 
buffer and incubated at 50 °C in a rocking incubator until lysed. Following lysis, an 
equal volume of phenol:chloroform was added to the cells, vortexed thoroughly and 
centrifuged at 13,300 rpm for 10 minutes. The top aqueous layer (containing the 
DNA) was transferred to a new tube; absolute ethanol was added at 2.5x the volume 
of the aqueous layer, and 3M NaAcetate was added at 0.1x volume of the aqueous 
layer. After a 30 minute incubation at -80 °C, the mixture was centrifuged at 13,300 
rpm for 30 minutes at 4 °C. The supernatant was removed and the pellet washed with 
cold 70% ethanol. After a final centrifuge at 13,300 rpm for 10 minutes the 
supernatant was again removed, with the tubes placed in a 37 °C heat block to 
facilitate drying of the DNA pellet. The pellet was suspended in 200 µl of clean Milli-
Q H2O and quantified using the Nanodrop. 
2.5.4.2 PCR 
The control primers for each target (and the bait) were used to amplify the target 
regions from genomic DNA.  
!  
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TABLE 2.10 -  PCR reagents 
Reagent Amount per 20 µl (reaction volume) 
10x PCR buffer (Invitrogen) 2 µl 
50mM MgCl2 0.6 µl 
dNTP (10 mM) 0.6 µl 
Forward primer (10 µM) 1 µl 
Reverse primer (10 µM) 1 µl 
Platinum Taq polymerase 0.2 µl 
Milli-Q H2O 13.6 µl 
HEK293 genomic DNA (509 ng/µl) 1 µl 
 
PCR was carried out in an Applied Biosystem Thermal Cycler 2.08. The protocol 
was optimised for each primer set as laid out in Table 2.10. All primers underwent 
an initial 4 minute stage at 94 °C, 35 cycles at optimised temperatures, and a final 10 
minute stage of extension at 72 °C. 
Table 2.11 -  PCR protocol,  35 cycles 
Target primers Denaturation Annealing Extension 
1.1 94 °C, 30 sec 50 °C 72 °C, 45 sec 
3.4 94 °C, 30 sec 61 °C 72 °C, 45 sec 
All remaining primers 94 °C, 30 sec 55 °C, 30 sec 72 °C, 45 sec 
2.5.4.3 Gel electrophoresis 
To determine the size of PCR products – indeed, if the PCR was even successful – 3 
µl of 6x loading dye was added to the PCR reaction mix and loaded onto a 1.5% 
agarose gel alongside a 1 kb plus ladder. To make the gel, 1.5 g of Ultrapure Agarose 
was dissolved in 100 ml TBE buffer. 10 µl ethidium bromide was added to the gel 
prior to setting. The gel was run for an hour and 15 minutes at 100V. Gels were 
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visualised and photographed using a BioRad UV light transilluminator using Quantity 
One Software. 
2.5.4.4 Purification of PCR product from gel 
Bands of the correct size (i.e. 300 bp for the bait and 150 bp for each target) were 
excised from the gel using a razor over a UV transilluminator and the DNA purified 
using the ZymoClean™ Gel DNA Recovery Kit. The protocol was carried out 
according to manufacturer’s instructions, with three small optimisations for better 
extraction: the wash step was performed three times (rather than two), the elution 
buffer was warmed to approximately 37 °C prior to being applied to the column, and 
once applied it was allowed to absorb for 1-2 minutes prior to centrifugation. 
2.5.4.5 Digestion 
Following purification of the target regions, the DNA was quantified using the 
Nanodrop spectrophotometer as outlined in section 2.3.3. Equimolar amounts of 
bait and target were then mixed and digested with Msp I overnight in a 37 °C water 
bath. Molar quantities of each target were calculated using Promega’s online BioMath 
Calculator tool [68], and reactions for each target were set up individually as outlined 
in Table 2.12. 





MspI 1.5 µl 
CutSmart buffer (10x) 2 µl 
Milli-Q H2O Up to 20 µl 
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Following overnight digestion, Msp I was inactivated by adding 2.6 µl of 10% SDS to 
a final concentration of 1.3%, and incubated in a 65 °C heat block for 20 minutes. 
2.5.4.6 Ligation 
The digested bait and target DNA was transferred to a 0.2 ml tube to which 2 µl T4 
ligase and 6 µl 5x ligase buffer was added. These were incubated at 16 °C for 4 hours, 
followed by a 30 minute incubation at room temperature.  
2.5.4.7 Specific amplification 
To ensure a clean template of known concentration (and only one conformation of 
bait+target DNA) for standard curve generation, the ligated DNA was subjected to 
another PCR using the same protocol outlined in section 2.5.4.2. The bait forward 
control primer and appropriate (for the specific ligation template) target reverse 
control primer were used. These PCR products were also run on a gel and extracted 
in the same way before being quantified using the Nanodrop spectrophotometer. 
2.5.4.8 qPCR 
To generate standard curves for each 3C primer pair, a Taqman qPCR was 
performed on each template using the appropriate primers and probe. A 10 ng/µl 
stock of each template was created, from which serial dilutions (1:10) were taken, 
producing a range of concentrations from 10 ng/µl to 10-9 ng/µl. The template used 
in the qPCR is shown in Figure 2.5. 





FIGURE 2.4 – DNA template for standard curve generation. This diagram 
shows the template created through digestion and ligation of genomic DNA. This is 
specifically amplified from the ligated fragments using the forward bait control 
primer, and reverse target control primer. To produce the standard curves for each 
interaction, the forward bait 3C primer and reverse target 3C primer are used, as is 
the Taqman probe for increased specificity. 
Table 2.13 -  Reagents used in 3C standard curve qPCR 
Reagent Amount per 20 µl (reaction volume) 
Kapa Sybr® master mix (2x) 10 µl 
Forward primer (bait, 10 µM) 1 µl 
Reverse primer (target, 10 µM) 1 µl 
Probe (10 µM) 0.6 µl 
Template DNA (dilution) 1 µl 













Bait control primer 
Bait 3C primer 
Taqman probe 
Interacting site 3C primer 







The qPCR was performed using Roche LightCycler® 480 II using the following 
programme: 1 cycle at 95 °C for 3 minutes followed by 45 amplification cycles of 3 
seconds at 95 °C, 20 seconds at 60 °C and 1 second at 72 °C. Data was then exported 
to Microsoft Excel for generation of standard curves and gradient information. 
2.5.5 Freezing chromatin 
Once standard curves were generated, the 3C proper could begin. Chromatin was 
frozen in HEK293 cells, and frozen MCF10A chromatin was provided by Jisha 
Antony of the Horsfield lab (University of Otago). 107 cells are required per 3C 
experiment, so forty-eight hours prior to chromatin freezing, 4x106 cells were seeded 
onto 6 plates (3 replicates, 2 no-ligase controls, 1 plate for counting prior to 
chromatin freezing to check cell number is correct i.e. the required ~10 
million/plate). 
Plate media was removed and replaced with exactly 18.9 ml media. 1.1 ml of 37% 
formaldehyde was added to the media in each plate for a final concentration of 2%, 
and the media gently swirled back over the seeded cells. The formaldehyde was left 
on the cells for 10 minutes before 1 ml of 2.5 M glycine was added to the media, 
which was again gently swirled back over the cells and left for 5 minutes. The media 
was poured from the plate and 20 ml of PBS was added to the wall of the plate to 
gently wash the cells before also being poured off. The wash step was repeated before 
addition of a final 10 ml of PBS directly to the plate surface. The adherent cells were 
then scraped from the bottom of the plate into suspension in the PBS, which was 
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then poured into a 50 ml Falcon tube kept on ice. 10 ml of PBS was again added to 
the plate to collect any remaining cells and added to the same tube. 
Once all plates were scraped, tubes were centrifuged at 320 g for 8 minutes. The 
supernatant was aspirated and the cell pellets were frozen at -80 °C until required. 
2.5.6 Cell lysis and digestion 
Cell pellets were retrieved from -80 °C storage and allowed to thaw on ice before 
being suspended in 5 ml of cold lysis buffer and incubated on ice for 10 minutes. 
The nuclei were then collected by centrifugation at 3000 rpm for 5 minutes at 4 °C. 
The supernatant was discarded and the pellet was resuspended in 0.5 ml of 1.2x 
CutSmart buffer before being transferred to a 1.5 ml Eppendorf tube. 7.5 µl of 20% 
SDS was added for a final concentration of 0.3%, and incubated for 1 hour at 37 °C, 
shaking at 200 rpm. 50 µl of 20% Triton X-100 was added for a final concentration 
of 1.8% and the incubation was repeated. 10 µl of each sample prior to digestion was 
then withdrawn and stored at -20 °C for later quality control. 8 µl of MspI (800U) 
and 45 µl of Milli-Q H2O was added to each tube and incubated overnight at 37 °C, 
shaking at 200 rpm. 
2.5.7 Ligation and reverse cross-linking 
To inactivate Msp I, 40 µl of 20% SDS was added to each tube for a final 
concentration of 1.3% and incubated at 65 °C for 20 minutes. Again, 10 µl was 
withdrawn (digested control) and stored at -20 °C. Each sample was then transferred 
to a 50 ml Falcon tube and 4.885 ml of Milli-Q H2O, 1.5 ml of 5x ligase buffer, 375 
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µl of 20% Triton X-100 (final concentration of 1%) was added and incubated at 37 °C 
for 1 hour. 200 µl of T4 ligase (200 U) was added to each tube and incubated for 4 
hours at 16 °C, followed by 30 minutes at room temperature. 15 µl of 20 mg/ml 
Proteinase K was then added and incubated overnight in a 65 °C waterbath. 
2.5.8 RNase treatment and DNA extraction 
To degrade RNA present in the sample, 30 µl of 10 mg/ml RNase A was added to 
each tube and incubated for 45 minutes at 37 °C. The samples were then subjected to 
three phenol:chloroform extractions – 7  ml of phenol:chloroform was added to the 
7  ml of sample and vortexed well. The sample was then centrifuged at 4696 g for 15 
minutes at room temperature and the aqueous phase transferred to a new 50  ml 
falcon tube. To preserve sample volume, as much of this phase was transferred as 
possible for the first two extractions, but great care was taken with the third extraction 
to avoid any phenol contamination of the next stage. In the second replicate, an 
additional chloroform step was carried out to thoroughly reduce phenol 
contamination – this step was carried out in the same way as the phenol:chloroform 
extraction, using chloroform (without phenol) instead. 
The DNA was then ethanol precipitated by adding 2.5 volumes of absolute ethanol, 
0.1 volume 3M NaAcetate, and 70 µl 10 mg/ml LPA. Sample was mixed by 
inversion and incubated at -80 °C for 2 hours. Following incubation the tubes were 
centrifuged at 4696 g for 1 hour at 4 °C. The supernatant was removed, 2 ml of cold 
70% ethanol was added (on top of the pellet – not to resuspend) and centrifuged at 
4696 g for 30 minutes, at 4 °C. Supernatant was removed and the pellet was allowed 
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to air dry for 5-10 minutes before being resuspended in 50 µl of H2O and stored at -
20 °C until required. 
2.5.9 qPCR 
To test any interactions in the DNA, qPCR was performed on each sample. 2 µl of 
the final product was used in a qPCR reaction with each set of primers, in the same 
protocol as was used to generate standard curves (outlined in section 2.5.4.8). The 
only change to that protocol was adjusting the volume of water to 5.4 µl to allow for 
larger volume of template DNA. Depending on resultant CP values, the qPCR was 
then repeated with varied template volume to obtain optimised results. 
2.6 STATISTICAL ANALYSIS 
All analyses were performed in Prism 6. Significance of the differences observed was 





Two large GWAS analyses have been published in recent years [1, 2], associating 
three groups of SNPs upstream of MAF with serum urate levels. These SNPs are in 
non-coding DNA, and their involvement in serum urate is unclear; in fact, none of 
these SNPs may even be causal. They may be in linkage disequilibrium (LD) with the 
causal SNP/s, meaning that they are so closely linked to the causal SNP such that 
they remain unseparated during recombination. A causal SNP is one in which the 
effect of the change in nucleotide impacts the function of the DNA sequence – being 
in non-coding DNA, this is likely to be disruption or attenuation of a regulatory 
element. Certainly not all the SNPs identified can be causal, and it remains to be 
determined which of the SNPs is responsible for variability in serum urate levels, and 
which are simply associated by proximity. Candidates for the causal SNP can be 
identified by performing a regression analysis to characterise the relationship between 
each SNP genotype and serum urate. SNPs with statistical significance will be those 
that have strong relationship that is consistently identified across participants. 
In order to identify candidate causal SNPs that are significantly associated with serum 
urate, an in silico analysis was conducted within publicly-available datasets from the 
United States. ARIC, CHS, CARDIA and Framingham (3rd generation) are large, 
long-running studies of cardiovascular disease that collect a wide variety of data from 
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large numbers of participants. These studies make their data available to researchers 
around the world, and were used in this project to identify SNPs that are correlated 
with serum urate levels.  
A regression analysis was conducted to characterise the relationship between SNPs 
(between 78 Mb and 81 Mb of chromosome 16) and serum urate levels, with the 
results meta-analysed and plotted using LocusZoom. A subset of the meta-analysis 
was created by sorting the SNPs according to statistical significance and selecting the 
top 1500 candidate SNPs from more than 5400. Figure 3.1 shows the results of this 
meta-analysis subset, in which each SNP is plotted according to –log P value (y axis) 
and position on chromsome 16 (x axis). 
 
FIGURE 3.1 -  LocusZoom plot showing f inal results of meta-analysis.  
This graph shows 1500 highest-significance meta-analysed SNPs plotted along the 
genome, between megabases 78 and 81 of chromosome 16 on the x-axis. Genes are 
shown along the x-axis and –log10 P values are along the y-axis (significance cut-off 
indicated by the dashed line). The colours of each SNP correspond to the degree of 
linkage disequilibrium (LD) that exists between that SNP and the SNP with the 
lowest P value, shown in purple. Red represents a strong chance of LD; orange, 
green and blue represent decreasing likelihood of LD. 
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Figure 3.1 shows that there were no SNPs of genome-wide significance (defined at a 
threshold of –logP ≥ 5) in the region surrounding MAF. Figure 1.1 (refer to 
Introduction) shows three distinct groups of SNPs upstream of MAF that have been 
associated with serum urate, which sit ~2 kb, ~60 kb and ~300kb upstream of the 
promoter. This analysis aimed to 1) replicate this finding in publicly available data 
and 2) provide one or more candidate causal SNPs for further analysis. However, 
this analysis included only 18,503 participants in total, compared to sample sizes of 
>140,000 and 71,149 in the Kottgen and Okada studies. Some of the SNPs identified 
in my analysis approached significance (-logP ≥ 5), and it is possible that significance 
was not reached due to a lack of power from limited subject numbers (see 
Discussion). 
The top ten most significant SNPs identified in this analysis are presented in Table 
3.1, with the position of SNP both on chromosome 16 and relative to the start of the 
MAF promoter. These SNPs are all outside the three groups previously identified 
upstream of MAF. Overall, this analysis identified no causal SNPs, and it remains to 
be determined whether the SNPs identified by the Okada and Kottgen studies play a 
functional role in controlling serum urate levels. 
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TABLE 3.1 -  Most-signif icant SNPs associated with serum urate in this 
analysis 
* The minus sign indicates an upstream (5´) position, while the plus sign indicates 
downstream (3´) position. 
3.2 DETERMINING APPROPRIATE CELL LINES FOR 
FUNCTIONAL ANALYSIS OF MAF VARIANTS 
Although identification of a causal SNP was unsuccessful in the in silico analysis, 
functional analyses can still be carried out on the three regions to identify possible 
roles the SNP regions can be playing, without identifying the single responsible SNP 
(or SNPs). To be associated with serum urate, these SNPs must have a function, and 
as they are within non-coding DNA, they are likely playing a regulatory role. One 
 SNP Position Distance from 
MAF promoter* 
(kb) 
-log P value 
1 RS7192327 80818428 1190.7 3.783834098 
2 RS16953530 80535215 907.5 3.621602099 
3 RS9925697 79141670 -486.1 3.602581458 
4 RS7192257 80525369 897.62 3.582694417 
5 RS2550595 78825324 -802.4 3.454074671 
6 RS7203024 80553903 926.2 3.318125878 
7 RS12443973 80403296 775.6 3.310069896 
8 RS16953272 80456733 829.0 3.290475644 
9 RS1510218 78958477 -669.3 3.212681243 
10 RS1809491 80440567 812.8 3.193413066 
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possibility is that they are influencing expression of the MAF gene. To investigate 
these regions, two experiments were performed: 1) a luciferase assay, to determine if 
certain putative regulatory elements within the third SNP region were capable of 
acting as an enhancer, and 2) chromosome conformation capture (3C), to identify 
interactions between the MAF promoter and the three upstream SNP regions. 
To undertake these in vitro experiments, selection of appropriate cell lines was 
required. These cell lines need to 1) transcribe the MAF gene, and 2) be related to 
cell types involved in serum urate/gout. qPCR was used to measure relative MAF 
expression in different cell lines. The luciferase assay requires a cell line with the 
correct transcriptional context (e.g. transcription factors), and for an enhancer 
hypothesised to interact with MAF, this means a MAF-expressing cell. Likewise for 
the 3C experiment, a cell line with active MAF expression is required to investigate 
the arrangement of chromosome 16 and interactions with the active MAF promoter. 
3.2.1 Expression of MAF in HEK293 and HeLa cells 
Two primer pairs were used to determine MAF expression levels – one pair 
(referred to as MAF) detects both the long and short variants of human MAF [57], 
while the other (designated MAF1) detects only the long variant [58]. This primer 
pair spans an exon-exon boundary, which once transcribed only exists in the long 
variant (variant 1); an expression assay uses transcribed cDNA (synthesised from 
RNA). Figure 3.2 is a schematic diagram demonstrating the transcriptional variants of 
MAF, and where the primers used in this analysis sit. The primers were validated to 
an external standard curve (Appendix III), producing efficiencies of 125.4% (MAF) 
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200.6% (MAF1). These primer efficiencies are not ideal – although the expression 
assay is relative, these primers are producing 1.25x and 2x the original template 
respectively. This produces a result that overestimates the true level of gene 
expression. Expression was normalised using the relative expression of three 
reference genes – GAPDH, RPL13A and CYCLOPHILIN. 
 
FIGURE 3.2 -  Schematic diagram displaying MAF  transcriptional 
variants.  MAF has two exons, allowing two transcriptional variants to exists. Variant 
1 retains both exons, while variant 2 consists of only the first exon. MAF primers 
detect both variants, as the primer pairs sit within this common exon. MAF1 primers, 
however, sit at the exon boundary, which means they only detect variant 1 (in 
transcriptional variant 2, this boundary does not exist). These primers are used to 
detect expression, so they are used in cDNA synthesised from RNA, i.e. exons only. 
!
For the first expression analysis, HEK293 and HeLa cells were tested. HEK293 cells 
are human embryonic kidney cells, and MAF expression has been shown in the 
proximal straight tubules of the zebrafish kidney [42]. HeLa cells are an immortal 
cervical cancer cell line and were readily available. HEK293 and HeLa are fast-
growing, easily transfectable workhorse cells that will be suitable for planned 
experiments, providing that they express MAF. 





Variant 1, coding size = 
5,443 bp 
Variant 2, coding size = 
1,122 bp 
5´                   3´               
! !
MAF – detects both 
variants 
MAF1 – detects long 
variant only 
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Figure 3.3 shows the expression of reference genes in HEK293 and HeLa cells. 
Reference gene primers have been previously validated and should detect expression 
at consistent levels between cell lines; this allows the expression of MAF to be 
normalised to baseline gene expression. Surprisingly, RPL13A was not detected in 
HEK293 cells, and as this gene produces a protein component of ribosomes it is 
extremely unlikely that this result is true. RPL13A was excluded as a reference gene 
for MAF expression, and it was not able to be determined why the RPL13A primers 
didn’t work. 
Figure 3.3 also shows MAF expression in these two cell lines. Using MAF primers 
(for both transcriptional variants), HEK293 cells express MAF 12-fold relative to the 
reference genes, while HeLa expressed MAF at similar levels to reference genes. 
MAF1 primers detected 5-fold expression of the short transcriptional variant in 
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3.2.2 Expression of MAF in HEK293 and MCF10A cells 
Due to the failure of RPL13A and the fact that many of the analyses produced 
primer dimers, the whole analysis was repeated. Primers were designed for this 
purpose, rather than taken from publications, as the previous primers had 
inappropriate efficiencies and produced primer dimers. The same HEK293 cDNA 
was used, and fresh MCF10A cDNA was synthesised. MCF10A cells are of human 
breast epithelial origin, and this makes them a preferable cell line (over HeLa) as 
they are non-tumourigenic. The analysis was replicated in the same manner as the 
first, using the same housekeeping genes as controls.!
The second expression analysis was a success. The primers were validated using an 
external standard curve (Appendix III) and produced an efficiency of 97.79%. Figure 
3.4 shows that the reference genes were expressed at reasonably consistent levels 
between the two cell lines, and the RPL13A was detected in HEK293. 
The new MAF primer pair (designated MAF2) detects the long variant of MAF only 
(as it spans an exon-exon boundary, also shown in Figure 3.2), and Figure 3.4 shows 
that MAF is expressed 3-fold over reference genes while MCF10A cells express very 
little MAF. An attempt at constructing the standard curve for this primer was made 
using MCF10A cDNA before such low expression levels were detected, and Table 
3.2 shows the CP values from this analysis. It shows that the detected expression is 
relatively consistent across a range of cDNA concentrations, supporting the results 
presented in Figure 3.4. In fact, at 100 ng/µl, MAF2 primers detect a CP value of 35 – 
this represents essentially no template at all. 
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Overall, MAF appears to be highly expressed in HEK293 cells – as MAF has 
previously been shown to be expressed in embryonic zebrafish kidney cells, 
expression in human embryonic kidney cells is unsurprising. The putative regulatory 
elements being investigated are upstream of MAF and the hypothesis is that they are 
involved in MAF regulation. Therefore, MAF-expressing cells such as HEK293s are 
appropriate for in vitro experiments. MCF10A cells appear to have very low 
expression and as such will provide an interesting comparison for the 3C experiment. 
In order to understand the chromosome conformation at active promoter and 
regulatory sequences, it is helpful to compare to non-active sites to further 
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Table 3.2 -  MAF  expression across various concentrations of MCF10A 
cDNA 






3.3 LUCIFERASE ASSAYS TO DETECT GENE EXPRESSION 
FUNCTION OF VARIANT REGIONS 
3.3.1 Background to the assay 
Of the three SNP regions upstream of the MAF promoter that have been previously 
identified in the literature, the third region (~300 kb upstream) has been a previous 
subject of study in the Horsfield lab. After thorough annotation of the three regions 
from ENCODE data, two fragments of this third region were highlighted as points of 
interest; both fragments contained signatures of regulatory elements that suggested 
they may be capable of gene regulation. The first fragment, hereby referred to as F1, 
contained binding sites for CTCF and cohesin. CTCF and cohesin are involved in 
3D spatial arrangement of chromatin, particularly in anchoring loops [31] [32]. F2, 
the second fragment, contains a histone mark (H3K4me1) associated with active 
enhancers. Both fragments contains DNase hypersensitivity sites, which indicate 
areas of accessible, open chromatin. Interestingly, F1 also contained two SNPs that 
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are present in gout patient sequences; F2 did not. Figure 3.5 summarises these 
annotations and where F1 and F2 lie relative to the MAF promoter. 
F1 was previously shown to be capable of insulator activity when tested in a zebrafish 
assay, although the SNPs did not alter this function. F2 had not been tested, although 
based on  annotation data was hypothesised to have putative enhancer activity. 
 
FIGURE 3.5 -  Schematic diagram il lustrating the location of and 
signatures at F1 and F2. At the far left of the diagram the MAF promoter is 
shown, with the three upstream regions of SNPs indicated to the right of MAF. F1 
and F2 are the focus of the luciferase assay and are found in the middle of the third 
SNP region, ~300 kb from the MAF promoter. Within each fragment are various 
signatures indicative of regulatory activity, taken from ENCODE data and 
represented schematically in this diagram. F1 contains CTCF and cohesin binding 
sites, areas of DNase hypersensitivity and two SNPs that have been found in gout 
patients. In F2, DNase hypersensitivity sites and a histone mark, H3K4me1 
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3.3.2 Transfection and analysis 
The recombinant plasmids were successfully transfected into HEK293 cells, at a final 
optimum cell density of 8 x 103 cells per well. Following transfection, the cells were 
suspended in luciferase substrate and resulting luminescence assayed using a 
luminometer plate reader. 
Four successful transfections were completed, with one being excluded from the final 
analysis due to outlying data points. Optimisation of the protocol conditions 
(including transfection direction and cell density) was ongoing throughout biological 
replicate production, and is therefore responsible for some variation in the data – this 
allowed conscientious removal of the fourth replicate.  
Cloning troubleshooting and luciferase optimisation can be found in Appendix IV. 
3.3.3 F1 is capable of enhancer activity, and gout SNPs increase 
enhancer activity 
All luminescence is normalised to pGL4.23-GW – the empty plasmid is also 
transfected at the same time as the test plasmids. pGL4.23-GW contains a minimal 
promoter, and as such will produce luciferase, leading to a baseline level of 
luminescence to which a comparison can be drawn. Data contained in Table 3.3 and 
represented in graph form in Figure 3.6 shows F1WT demonstrated enhancer 
activity, producing on average 26.7% more luminescence than pGL4.23-GW (p = 
0.012). F2 was not shown to have enhancer activity, and in fact showed decreased 
luminescence – on average, 74.3% that of pGL4.23-GW (p = 0.0146). F1SNP was 
also shown to have enhancer activity, and in fact the SNPs contained in this fragment 
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caused it to have an increased enhancer effect. F1SNP produced 65.9% more 
luminescence than pGL4.23-GW alone (p < 0.0001) and 30.9% more luminescence 
than F1WT (p = 0.0011) – the same piece of DNA, but without the SNPs. These 
results are all statistically significant, and show that these SNPs present in gout 
patients are capable of altering function of a regulatory element. 
Table 3.3 – Normalised luciferase assay results (pGL4.23-GW = 1),  al l  
presented in relative luciferase units (RLU) 
F1WT F1SNP F2 
1.196 1.668 0.705 
1.250 1.529 0.691 
1.355 1.780 0.832 
1.267 1.659 0.743 
!
TABLE 3.4 -  Statist ical analysis of luciferase assay results 
Comparison P value 
pGL4.23 vs. F1WT 0.012 
pGL4.23 vs. F2 0.0146 
pGL4.23 vs. F1SNP < 0.0001 




FIGURE 3.6 – Upregulation of luciferase activi ty in response to F1. A) 
Schematic diagram demonstrating where F1 and F2 lie relative to the MAF 
promoter, and what signatures are present at each fragment. B) The average results 
of three biological replicates +/- standard error of mean (SEM) are presented in 
relative luciferase units (RLU) in reference to the empty pGL4.23 plasmid. F1WT 
exhibits enhancer activity (*p = 0.012), as does F1SNP (****p < 0.0001). F1SNP 
exhibits greater enhancer activity than F1WT (**p = 0.0011), while F2 does not 
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3.4 CHROMOSOME CONFORMATION CAPTURE 
Having established that one of the SNP regions identified in GWAS contains at least 
one regulatory element, and that SNPs (present in gout patients) within it alter ability 
to regulate transcription in vitro, it is important to determine the target genes of such 
regulatory elements. MAF is the closest gene to the groups of SNPs identified in non-
coding DNA, and represents a good candidate gene for regulatory elements 
contained in these regions to be interacting with. Chromosome conformation capture 
(3C) was carried out to investigate the spatial arrangement of selected regions of 
chromosome 16 around the MAF promoter. To perform 3C, the MAF promoter 
was selected as the ‘bait’ or anchor, with targets selected from each of the three 
upstream SNP regions. Special attention was paid to the two putative regulatory 
regions in the 300 kb upstream group, particularly F1. F1 has been shown to have 
both enhancer and insulator ability, and two SNPs present in gout patients can 
increase the enhancer ability of this element (Figure 1.6). Therefore, if an interaction 
is occuring between these elements and the MAF promoter, that would be strong 
evidence that this system plays a role in presentation of elevated serum urate and 
perhaps, gout. Nevertheless, it is interesting to characterise an area of the chromatin 
and to determine what interactions – if any – are happening in the area. 
3.4.1 Experimental design 
Performing a 3C experiment consists of two arms – the experimental arm, and the 
quantitative arm. Figure 3.7 outlines the overall structure in schematic form and is a 
reference for the remainder of the chapter. 
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The experimental arm of 3C involves capturing the interactions of DNA by 
crosslinking the DNA using formaldehyde – this freezes any interaction in place. The 
DNA is then digested using MspI (in this case), which has been selected based on its 
proximity to regions of interest and its ability to resolve F1 and F2. Following excess 
dilution (to decrease the frequency of proximity-dependent ligation, and increase the 
relative frequency of “true” interactions) the mix is ligated, which means that any 
DNA cross-linked together (i.e. interacting DNA) will become joined. The 
crosslinking is then reversed and the DNA extracted, ready to undergo a primer-
probe qPCR. This qPCR has been designed to detect interacting DNA with a 
forward primer in the bait region (MAF promoter) and reverse primers in each of the 
7 targets (shown in Figure 3.8). The probe is also within the bait region, only 2 bp 
from the MspI site to ensure only specific amplification is represented in the final CP 
value. 
The output of 3C is quantitative, in that the frequency of ligation of captured 
fragments is compared with the frequency of random background ligations.  
Quantitation is achieved by using TaqMan qPCR with primers and probe detecting 
the specific bait-target ligation products. Before this can happen, qPCR standards 
have to be made artifically, that represent each bait-target interaction.  Then using a 
dilution series, standard curves can be generated against which 3C amplification is 
quantified for each predicted interaction. Therefore, the quantification arm was 
carried out first to generate standard curves for measuring 3C interactions in the 
experimental arm. 
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The first step of creating standard curves is to isolate the DNA surrounding the 
relevant restriction sites – that is, the MspI sites directly adjacent the bait and each 
target. This is done using “control” primers, a set of primers either side of the 
restriction site. Importantly, these primers must sit outside the primers that will be 
used in the final qPCR analysis of the 3C experiment, as they are amplifying the 
template of the 3C primers. Figure 3.8 is reproduced here from section 2.5.3, and 
demonstrates the placement and design of primers at both the bait and target MspI 
sites.  
Once the restriction sites and surrounding DNA are isolated, the bait and target sites 
are all mixed in an equimolar quantity and subjected to digest. This creates sticky 
ends at each site, allowing them to ligate in the next step. After ligation has occurred, 
another PCR is conducted on the mix using the same control primers – however, this 
PCR uses the forward control of the bait, and the reverse primer of each target (see 
Figure 2.6 for a schematic diagram of the product of this PCR). This produces what 
is called an artificial fragment or template – it is the prototype template for the 
hypothesised interactions. It is artficially generated in this way – amplified from 
genomic DNA, digested and ligated directly – to provide a pure solution of 
anticipated 3C product, to allow the efficiency of the 3C primers to be calculated. It 
also allows production of standard curves, which are used in the final 3C analysis to 
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FIGURE 3.8 -  Schematic diagram of control and 3C primer placement 
at bait  and target si tes. 
!  
FIGURE 3.7 – Schematic diagram out lining the process of 3C. 
(Previous page) Both the experimental (black boxes) and quantification (purple 
boxes) arms are shown. The MAF promoter (bait) is represented as a green 
arrow, with the blue box representing a putative regulatory element, or target. The 
experimental arm of 3C involves cross-linking protein-DNA/DNA-DNA 
interactions using formaldehyde, followed by digestion using MspI. The DNA is 
then diluted highly to reduce the frequency of proximity-dependent interactions 
and ligase added. Finally, the crosslinking is removed and 3C primers used in a 
primer-probe qPCR to identify interacting DNA sequences. In the quantification 
arm, relevant MspI sites (next to bait and targets) are amplified from genomic 
DNA using control primers and subjected to digest in equimolar quantities. The 
fragments are then ligated together and the specific conformation of bait + target 
selected using PCR with the control primers again, only this time the bait forward 
primer + target reverse primer are used. Following this, the sample is diluted over 
a series and used to perform an identical qPCR as the one at the culmination of 
the experimental arm. 
Bait control primer 





Target control primer 























Specifically for this experiment, targets were designed along the three SNP regions of 
interest identified in GWAS analyses. A detailed explanation of target design can be 
found in section 2.5.1, and Figure 2.3 outlines the positions of the targets relative to 
the MAF promoter. Part of this figure is reproduced below for clarity. 
  
3.4.2 Standard curve construction – PCR troubleshooting 
The first stage of constructing standard curves for 3C is to amplify the relevant 
restriction sites from genomic DNA using the “control” (outside) primers (Figure 3.7, 
quantification arm 1; also see Figure 3.8B). HEK293 genomic DNA was extracted 
using a typical phenol:chloroform/ethanol precipitation technique from a flask of 
cultured cells. Endpoint PCR was then used to amplify the restriction sites, prior to 
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FIGURE 3.9 -  Target select ion and primer placement. The legend 
shows what each primer has been designated, and where these primers sit in 
relation to the MAF promoter. 
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Figure 3.10 shows the results of this PCR. The bait site, as well as 2.1, 2.2, 3.1, 3.2 
and 3.3 all amplified perfectly, with a correct-sized band and no contamination in the 
no-template control (NTC) (with the exception of the bait, although this product in 
the NTC simply appears to be a small amount of overflow from the neighbouring 
well). From this gel, all true products (therefore, not including 1.1 and 3.4) were 
excised from the gel and purified. 
 
FIGURE 3.10 – Agarose gel showing PCR products amplification in constructing 3C 
standard curves (refer to Figure 3.7). The bait primers produced a band of ~300 bp 
(correctly, lane 1), while most other primers produced correct bands of ~150 bp – all 
primers except 1.1 (lane 3) and 3.4 (lane 15). These primers produced non-specific 
products and as such must be optimised. Refer to Figure 3.8 for position of primers 
in relation to MAF. 
 
             1          2          3         4          5           6 














3.4.3 Standard curve construction – control primer optimisation 
As 1.1 and 3.4 were producing non-specific amplicons, the primers were subjected to 
a range of annealing temperatures, using HEK293 DNA as template. This was 
carried out to determine the ideal temperature for each primer pair using a 
temperature gradient PCR machine. Figure 3.11 shows the result of this PCR. The 
temperature which produces the strongest band at 150 bp and reduces non-specific 
as much as possible is considered the optimal annealing temperature for the primer 




FIGURE 3.11 – Agarose gel showing products of temperature-gradient 
PCR. Each set of primers was tested across a range of six temperatures: 50.3 °C, 
51.8 °C, 54.7 °C, 58.2 °C, 60.2 °C and 61.0 °C. The red line on the gel indicates 
products of 1.1 primers, while the blue line indicates the products of 3.4 primers. An 
annealing temperature of 50.3 °C produces the strongest band at 150 bp for the 1.1 
primer, although non-specific streaks do not appear to change significantly. 61 °C 
produces the strongest 150 bp band for the 3.4 primer, and minimises much of the 
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Following optimisation, a standard endpoint PCR was carried out to isolate the 
restriction sites at region 1.1 and 3.4. Figure 3.12 shows the results of this PCR 
visualised on a 1.5% agarose gel. The bands produced are clear and of the correct 
size,! allowing neat excision of the desired DNA amplicon for downstream use. 
!
  
FIGURE 3.12 -  Agarose gel showing the product of 1.1 and 3.4 
amplif ication from genomic DNA. Following optimisation, the standard 
endpoint PCR was repeated using the 1.1 and 3.4 primers in HEK293 genomic 
DNA at optimised temperatures. This PCR produced clear 150 bp bands which 
could be neatly excised from the gel without non-specific contamination. The red 
boxes indicate the area that was purified from the gel.  
!
3.4.4 Standard curve construction – digestion and ligation optimisation 
Once the individual restriction sites are isolated, the next step is to mix the DNA in 
equimolar quantities, digest each site, and ligate the DNA to create artificial templates 
for standard curves to be produced from. These artificial fragments are to replicate 









For the first attempt, DNA was mixed and Msp I added for a total incubation time of 
three hours. After enzyme inactivation the mix was split into two PCR tubes and 
ligation initiated. Incubation was overnight in the ThermoCycler, hence the division 
of the digestion mix. The products of this process were run on a 1.3% agarose gel the 
next morning and is shown in Figure 3.13. Both lanes are identical product, and 
following ligation a large pool of 300 bp products is anticipated – if digestion was 
efficient, each amplified site should be cut by MspI and therefore have identical 
sticky ends. Selection comes in the form of size differentiation – the desired bait end 
is 200 bp, while the desired target end is 100 bp. The unwanted ends of each site are 
specially designed, and are either 100 bp (bait) or 50 bp (target). This means the only 
product that is 300 bp will be the artificial templates, with a small amount being the 
original bait fragment. However, of the DNA in this mix, the bait comprises only 
one-eighth, so the other fragments would ligate at a higher frequency to the bait than 
the unwanted bait half. However, as is shown in Figure 3.13, there is no band 
whatsoever at 300 bp. It is good that both lanes are essentially identical, but this stage 




FIGURE 3.13 – Results of digestion and l igation in the construction of 
3C standard curves. Following digestion and ligation, the products were run on a 
1.3% agarose gel. A pool of DNA – visualised as a large band – should be present at 
300 bp. The DNA that is present will be various concatenates, an unavoidable result 
of using one restriction enzyme on all the DNA fragments. Each digested fragment 
has a multitude of options for ligation, as a pool of DNA with identical sticky ends 
will inevitably produce unwanted ligation products. 
 
In repeating this step, the sites were all kept separate – i.e. there was no 
digestion/ligation “pool”. Each target site was mixed with the bait site in an equimolar 
ratio, and only one target site was present in each tube. This means that the bait and 
target are in a 1:1 ratio and increases the chance of a correct ligation product being 
produced for each target site. In the previous attempt, with all targets being mixed 
with the bait, there was seven times the amount of target DNA to bait DNA – 
although each site was present in equimolar quantities, each target needs to ligate to 
the bait and the ratio was therefore 1:7, limiting the likelihood of getting all the 
required ligation products. 
With seven tubes containing the bait and target sites, the digestion was incubated 








for 4 hours (instead of overnight) and then an hour at room temperature. A standard 
endpoint PCR was then carried out on each ligation mix, in order to specifically 
amplify the correct concatenate or conformation of the artificial template. Figure 3.14 
shows the results of this PCR after being run on a 1.5% agarose gel. 2.2, 3.1, 3.2 and 
3.3 all amplified successfully, with various bands produced. This is as expected, as 
the DNA in the ligation mix was produced from genomic DNA using these same 
primers, and following ligation there will be DNA of different sizes containing the 
primer binding sites. However, the 300 bp band is the correct size of the artificial 
template, and sequencing confirmed the identity of these bands following gel 
purification. This DNA was quantified and serves as the template for the standard 
curve qPCR. It is important that only one conformation of the template is present in 
the template, as the known quantity of DNA is vital in downstream applications 
(constructing and using the standard curves). 1.1, 2.1 and 3.4 did not successfully 
amplify in this experiment. 
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Figure 3.14 – Agarose gel showing the results of a PCR to amplify 
art i f icial  template for 3C standard curve. Following ligation, the mix was 
subjected to a PCR to amplify the correct conformation of the artificial template, 
using control primers (bait forward and target reverse). Lanes A5, A7, A9 and A11 
show successful amplification in 2.2, 3.1, 3.2 and 3.3 respectively, producing a 300 
bp band that could be carefully excised and purified (indicated in red box on gel). All 
other primer pairs fail to amplify product (lanes A1, A3 and B1). All other lanes 
carry NTC. 
The same PCR was repeated in the 1.1, 2.1 and 3.4 ligation mixes to obtain pure 
template for the standard curves. This was unsuccessful, so digestion and ligation was 
again repeated for these three sites. At the PCR stage, 1.1 this time produced bands 
at 300 bp but 2.1 and 3.4 remained unsuccessful. A further attempt at this PCR in 
2.1 and 3.4 yielded no product again, and due to time constraints no further efforts 
were made to produce artificial template with these sites. Figure 3.15 represents the 
successful primer regions that were able to produce standard curves, as well as their 
relative position to MAF. 
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3.4.5 Standard curve construction – qPCR 
In the sites that had succesfully undergone artificial template production – 1.1, 2.2, 
3.1, 3.2 and 3.3, Figure 3.15 – qPCR was used to construct standard curves to allow 
quantification of any 3C results. The template DNA was diluted to an initial 
concentration of 10 ng/µl, and from this solution 10 serial dilutions (at a 1:10 
fraction) were carried out. This gives ten standard curve data points, at concentrations 
ranging from 10 ng/µl to 10-9 ng/µl. Primer-probe (Taqman) qPCR was used to 
quantify the product from each template concentration, and primer efficiency and 
standard curves were produced. Figure 3.16 shows the standard curves from the five 
primer pairs tested, with CP values plotted against log template concentration. All 
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FIGURE 3.15 - Schematic diagram representing the primers for 
which successful  standard curves were generated.  Successful primers 
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TABLE 3.5 – Primer eff iciency results from 3C standard curves 
 
3.4.6 First 3C technical replicate 
The first 3C replicate was carried out in four sets of chromatin – two HEK293, two 
MCF10A. One replicate of each cell line was used as a no-ligase control, allowing 
spontaneous re-ligation and inefficient digestion to be controlled for in the final 
analysis. The no-ligase control is used to show what level of amplification is produced 
in the absence of ligase, and is therefore considered to be background and not a true 
interaction to be measured. 
The result of the first qPCR analysis was that there was no amplification in any well – 
all primers were used with 2 µl of 3C DNA. 
Undigested and digested DNA samples taken during the 3C protocol was 
subsequently diluted in Tris-HCl and treated with proteinase K before being run on a 
0.6% gel, alongside 3C DNA, to observe digestion and ligation efficiencies. Figure 
3.17 shows this gel, which also includes samples from subsequent analyses. The gel 





eff iciency (%) 
A 1.1 -3.7677 0.99938 84.25 
B 2.2 -3.2646 0.99642 102.45 
C 3.1 -3.4274 0.99754 95.78 
D 3.2 -3.2859 0.9859 101.53 




shows that there is possibly a higher density of low fragment size DNA in the digested 
samples vs. the undigested samples, although it is not particularly strong. 
Furthermore, one would expect a smear of DNA on the gel in the undigested lanes, 
but this is not apparent. However, there is a clear shift in the HEK293 3C (with 
ligase) and 3C no-ligase lanes as indicated on the figure, suggesting that the digestion 
and ligation have been effective in this cell line. There is no change in MCF10A 
lanes, suggesting that the digestion has not been efficient.  
 
FIGURE 3.17 – 0.6% agarose gel showing the results of two 3C 
technical replicates,  3 biological replicates.  Red asterisks on the gel indicate 
the first replicate, while blue indicate the second replicate. Refer to Figure 3.7 for an 
outline of 3C process. Lanes 1 and 2 contain undigested HEK293 DNA, and lanes 3 
and 4 contain undigested MCF10A DNA. Lanes 5 and 6 contain digested HEK293 
DNA, and lanes 7 and 8 contain digested MCF10A DNA. Based on these lanes, it 
appears that digestion has worked, although it cannot be strongly supported by this 
gel. Comparing undigested and digested DNA can qualitatively determine the 
digestion efficiency, as undigested DNA should appear as an aggregation at the top of 
the gel, while digested DNA should appear as an even smear down the lane. This is 
not the case with this gel, although it does appear that there is a higher concentration 











of small fragments in the digested DNA (particularly in the MCF10A DNA). It is 
possible that this DNA has degraded prior to being run on the gel. 
Lanes 9 to 11 show HEK293 3C biological replicates 1-3, and lane 12 shows 
HEK293 no-ligase control DNA. Lanes 13-15 show MCF10A 3C biological 
replicates 1-3 and lane 16 shows MCF10A no-ligase control DNA. This gel shows 
that digestion and ligation in HEK293 first biological replicate was a success, due to 
the shift in band size on the gel. Smaller fragments in the no-ligase control suggest 
that the DNA is cut into small fragments, and the high band size in the 3C-ligated 
DNA suggests the these small fragments were ligated successfully. In the second two 
biological replicates, it appears that the DNA is at a much lower concentration than 
in the first replicate, despite having equal volumes loaded (20µl). Tentatively, it seems 
that the HEK293 digestion/ligation has been successful. MCF10A appears not to 
have worked because the no-ligase control appears to be uncut. 
 
To further test the 3C DNA, the final qPCR step was repeated with both greater and 
lesser quantities of template. At least in the HEK293 reaction there appears to have 
been success, so perhaps the first qPCR was inhibited by factors in the DNA (phenol 
contamination or simply too much DNA), or perhaps there was not enough template 
to draw amplification from. The qPCR was repeated using 0.2 µl, 0.5 µl, 1 µl and 8 
µl of template per reaction. As a positive control for the reaction, standard curves for 
3.2 and 3.3 primers were generated on the same plate (section 3.4.5). 
The standard curves were successfully generated, but there was no amplification in 
any 3C template. After researching 3C troubleshooting, it appears that 50-100 ng of 
template was the optimal quantity for a result, so the 3C DNA was quantified using a 
ThermoFisher Qubit® Fluorometer. The concentrations of DNA (presented in 
Table 3.6) were lower than expected, and it became apparent that the previous qPCR 





Chromatin sample Concentration (ng/µl) 
HEK293 228 
HEK293 no ligase 330 
MCF10A 208 
MCF10A no ligase 237 
 
3C is a very difficult experiment to design a positive control for, as the design is so 
particular. In order to use a positive control, a known interaction must be included in 
the experiment design to produce an expected result. Primers from a previous 3C 
performed in the Horsfield lab were available and known to produce a result from 
interacting DNA, albeit in a different cell line and with a different restriction enzyme. 
A final qPCR was carried out using exactly 75 ng of 3C DNA with all primers, plus 
the additional putative positive control. Unfortunately, this experiment also failed to 
produce any amplification. 
3.4.7 Second 3C technical replicate 
Despite repeated attempts to produce amplification in the first replicate, there 
appeared to be some sort of technical barrier to a result. qPCR is a highly sensitive 
tool for detecting presence of DNA, and it is surprising that there was no interaction 
whatsoever to be detected, particularly in the 1.1 region; this site is only ~7.5 kb from 
the bait and some low-level interaction based on proximity would be expected. 




Therefore, a second 3C technical replicate was carried out. The protocol was 
repeated in this replicate with one modification – an extra chloroform extraction step 
following phenol:chloroform extraction (and preceding ethanol precipitation). This 
was to ensure the final preparation of DNA was totally free of phenol, a known 
contaminant of qPCR reactions. 
2 µl of 3C template was analysed using each primer. Results of this qPCR are 
presented in Table 3.7. There was no amplification whatsoever in one HEK293 
biological replicate and one MCF10A biological replicate. In the remaining 
replicates, 3.1 produced late amplification in HEK293 chromatin (but not MCF10A), 
and one of the qPCR calls was uncertain.  1.1 and 3.4 both produced amplification in 
MCF10A chromatin only, all at CP values of ~29.  
TABLE 3.7 – Summary of qPCR results from second 3C technical 
replicate 
Replicate Result 
HEK293 1 No amplification 
HEK293 2 Amplification at region 3.1 (CP = 32.9, 
33.11, this second call was uncertain) 
MCF10A 1 No amplification 
MCF10A 2 Amplification at regions 1.1 (CP = 29.11, 
29.16) and 3.4 (CP = 29.83, 29.75) 
 
Following these interesting results, the products of amplification were purified and 




3.18 shows both MCF10A lanes produced clear bands at 200 bp and faint bands at 
150 bp, where the expected product should sit. 3.4 in MCF10A produced an 
additional band at 300 bp, which may be the product of two sets of interacting 
fragments ligating together. The amplified product of 3.1 in HEK293 is inconclusive 
based on the gel result – there is no clear band, only a smudge below 100 bp. 
 
Figure 3.18 – Results of qPCR amplif ication in the second 3C 
replicate. 1) 1.1 in MCF10A shows a clear band at 200 bp and a faint band at 150 
bp, the size of the expected product. 2) 3.4 in MCF10A exhibits the same bands as 
1.1, with an additional band at 300 bp. 3) 3.1 in HEK293 is inconclusive – there is 
no clear band, but an indeterminate mark just under 100 bp (these are most likely 
primer dimers). The expected product size of each lane is 150 bp. 
 
Results of sequencing were also unclear (Appendix V). As expected from a qPCR 
analysis, many products other than those desired are amplified, particularly as the 1.1 
and 3.4 primers are likely to have non-specific binding due to the difficulty of 
obtaining primers at those sites. However, only specific products should produce 










fluorescence due to sensitivity of the Taqman assay technique. Therefore when 
sequencing results were received, it was unsurprising, albeit unhelpful, that there was 
not one clear sequence produced. In hindsight it would have been best to run the gel 
first, excise the correct-sized band and send that for sequencing. 
The 3C DNA was run on a 0.6% gel to visualise the size/presentation of the total 
DNA in comparison to the first replicate and no-ligase control. Shown in Figure 3.18, 
all four replicates appear to be at very low concentration. Aside from this, there are 
faint bands in the HEK293 DNA matching that of the first replicate, while the 
MCF10A DNA is inconclusive. To quantify the amount of DNA present, a 
ThermoFisher Qubit® Fluorometer was used. Shown in Table 3.10, the DNA was 
found to be at a surprisingly low concentration, particularly when compared to results 
from the first replicate (Table 3.8). Perhaps retrieval of the aqueous phase was too 
conservative out of fear of phenol contamination. 
Replicate Concentration (ng/µl) 
HEK293 1 56.1 
HEK293 2 75.2 
MCF10A 1 26.9 
MCF10A 2 48.9 
 




In terms of true results, 3.1 is unlikely; the original qPCR call was uncertain, 
sequencing was inconclusive and the gel result was unconvincing. The other two 
results, however, are marginal. They may be true, but they may simply be an artefact 
of the protocol or spontaneous re-ligation. In conclusion, the 3C overall was not a 
success within this timeframe, and without further analysis and troubleshooting it is 
difficult to conclude that the regulatory regions identified interact with MAF from 






4.1 DETERMINING CAUSAL SNPS NEAR THE MAF GENE THAT 
COULD REGULATE SERUM URATE LEVELS 
In Aim 1 of this work, this study sought to identify a causal variant from the SNP 
region upstream of MAF. The literature currently shows a correlation between this 
general non-coding area and serum urate, but without solid functional data it is 
impossible to prove causation. The purpose of the bioinformatics analysis was to 
identify one or more candidate causal SNPs for functional analysis. Identifying a SNP 
from this group is important in order to find the reason for the association with 
serum urate through functional tests, and to apply meaning to GWAS results. 
This attempt was unsuccessful, but that is certainly not to say there are no causal 
SNPs in this region. The most important factor to consider is sample size – this 
analysis considered only 18,503 participants, not to mention that they were pulled 
together from four different studies. These studies use different methods and SNP 
chips to genotype participants, which means that different SNPs are captured in each 
study. Although there is overlap, this means there are SNPs within this analysis that 
aren’t represented in all participants. Therefore, any strong relationships with these 
SNPs will not be captured. Furthermore, SNPs in this analysis were approaching 




(Okada) and >140,000 (Kottgen). In my opinion, this meta-analysis simply didn’t 
have the power to reach statistical significance. 
A smaller point, but an important one to raise, is the fact that individuals of different 
ancestral backgrounds were included. Although the effect of ancestral differences is 
controlled through the creation of subject lists, it stands to reason that these lists do 
not entirely negate this effect. Different populations have different allele frequencies 
due to ancestral effects – founder effect, genetic drift, age of population, etc. So if a 
group is particularly susceptible to elevated serum urate, then SNPs at a higher 
frequency in their population may rise to significance in a study that does not 
properly control for ancestral differences. In this case, the SNPs identified are really 
linked to genetic ancestry and not necessarily serum urate. 
In order to find a causal candidate upstream of MAF, a much larger analysis must be 
undertaken. For example, a combined analysis of the Kottgen and Okada data would 
be interesting, especially if the three distinct groups could be resolved and one highly 
significant SNP identified from the dataset. Otherwise, analyses in strict single-
ancestry datasets would be of great value, to minimise the effect of ancestral 
differences as far as possible. New statistical methods are growing in use in GWAS to 
replace ideas of race and ethnicity, which are complex sociocultural constructs and 
typically have vague definitions in human genetics studies [69]. These methods may 





4.2 IDENTIFICATION OF GENE REGULATORY FUNCTIONS FOR 
REGIONS CONTAINING URATE-ASSOCIATED SNPS 
Urate-associated variants were present in an intergenic region upstream of the MAF 
locus. In Aim 2 of this work, this study tested the hypothesis that one or more of 
these associated SNPs lies within a regulatory element, and that the variant SNP 
alters the function of this regulatory element. A luciferase assay was carried out to 
determine the function of two fragments within the 300 kb region upstream of MAF. 
One, F1, had already been shown to exhibit insulator activity in a zebrafish assay [42]. 
The other was a putative enhancer based on the histone marks present at sites of 
DNase hypersensitivity. However, when the assay was completed it showed F1 was 
also capable of enhancer activity (p = 0.012) while F2 was not. Two interesting results 
arose from this assay: 1) two SNPs contained in F1 (isolated from gout patients) were 
shown to increase enhancer activity of the regulatory element (p = 0.0011), providing 
evidence of a function-altering SNP upstream of MAF, and; 2) F2 was shown to 
actually decrease gene expression (p = 0.0146), in that the F2 plasmid produced less 
luminescence than the empty, minimal promoter plasmid. Although this assay 
specifically tests for enhancer activity, this is an interesting observation. Future 
experiments would certainly involve cloning this fragment into a zebrafish insulator 
assay, much in the same way F1 was characterised, in order to determine if F2 is in 
fact capable of insulator activity. 
In terms of the function-altering SNPs in F1, this is a very exciting result. The two 




both are), but the result produced in this study is very promising. The observation 
that these urate-associate SNPs upregulate enhancer activity raises the possibility that 
they could influence the regulation of genes targeted by the enhancer. Since MAF is 
the nearest gene, it is likely (but not certainly) the target of the enhancer and its 
expression could be influenced by the SNPs. 
Further work is needed to characterise the actual gene target of the regulatory 
elements containing the urate-associated SNPs. Which gene(s) does this element 
regulate and in which tissues is it active? A 4C experiment could be designed to 
investigate this further – 4C is similar to 3C except that rather than selecting targets 
that are hypothesised to interact with a bait, only a bait is selected (in this case, F1 
would be the bait) and all interactions with that DNA sequence are captured. To 
identify tissues in which the enhancer is active, an enhancer vector assay could be 
carried out in zebrafish. This involves cloning F1 into an enhancer vector containing 
a minimal promoter upstream of GFP, and microinjecting this construct into one-cell 
zebrafish embryos. As the zebrafish develop, the enhancer will drive GFP 
fluorescence in tissues in which it is is active. For example, if GFP expression is 
observed in kidney, then it is likely that the enhancer will normally be controlling 




4.3 DETERMINING IF REGULATORY ELEMENTS INTERACT 
LONG-RANGE WITH THE MAF GENE 
Since urate-associated SNPs were able to influence the gene regulatory function of 
the DNA they resided in, it was all the more important to determine if these regions 
were able to interact with the nearby candidate gene, MAF. In Aim 3 of this work, 
this study sought to determine if identified regulatory elements interact long-range 
with the MAF gene. This would reveal the potential of SNPs in regulatory elements 
that contact the MAF gene to alter gene regulation, possibly leading to atypical serum 
urate levels. A 3C was conducted to identify such interactions, but unfortunately the 
results of the 3C were inconclusive at best. Despite extensive troubleshooting it 
appears that the 3C has been a technical failure, rather than a true negative result. It 
is highly unusual for a qPCR to not amplify anything at all, as it is a very sensitive 
technique. The whole 3C protocol has been used before by multiple people with 
success, and the primers all worked very well. With the time constraints inherent in 
this study, the experiment was unable to be optimised. 
One difficulty with designing a 3C experiment is the problem of a positive control – 
many 3C experiments do not contain them, as it requires the inclusion of a known 
interaction in a specific cell-line. This interaction has to be validated with the specific 
primers, restriction enzyme and cell line before it can be used and this is often 
unfeasible. Had time allowed, effort certainly would have gone into obtaining a 




Furthermore, perhaps HEK293 cells were not the best choice. They were readily 
available and easily transfectable, but in terms of integrity the cell line is of 
questionable value. The creator of the cell line himself has expressed doubt as to the 
origin of the cells – being embryonic, it is very difficult to say with certainty that the 
cells are of the kidney. In fact, they demonstrate many characteristics of neuronal 
cells [70, 71]. This may affect the 3C result if the upstream regulatory elements are 
kidney-specific and only interact with MAF in true kidney cells. 
MAF is highly expressed in both HepG2 (liver) and K562 (leukemia) cells, which fits 
in with other knowledge about both MAF and serum urate/gout. The liver is an 
important organ in the processing of urate [3], and MAF is important in 
differentiating the liver in development [37]. Leukemia is a cancer of white blood 
cells, linking MAF back to the immune system where its importance is well-
emphasised. 
An interesting source of further data is publicly-available Hi-C data [72]. This gives 
information about domain structures that are conserved across cell types – these are 
hotspots of interaction. Figure 4.1 shows the Hi-C data at the MAF locus in NHEK 
cells (keratinocytes), where MAF is at the boundary of a domain. This means it could 
interact with either domain – towards the SNPs, or away from the SNPs. Sitting at a 
domain boundary could mean that this a possible mechanism by which MAF can be 
regulated in different tissue types, such as the lens of the eye and immune cells. 




domains, and MAF may interact with different domains depending on the tissue 
type. 
 
FIGURE 4.1 – Hi-C output showing interaction domains at MAF  and 
upstream. This heatmap is produced from Hi-C data [72] and shows hotspots of 
interaction across chromosome 16. MAF is indicated in the green box on the 
alignment at the top, along with the three SNP regions in the orange box. Domains 
are defined as the boxes of high density within the map, and these are typically 
conserved across cell lines. This map is taken from NHEK data (a keratinocyte line), 
but these domains should be representative of chromatin structure in most human 
cells. MAF is shown right at the edge of two domains, which means it may interact in 
either direction – perhaps in the same domain as the SNPs, perhaps it is closed from 
the SNPs and is instead interacting in the other domain. To determine directionality, 








Finally, an interesting paper was published during the course of this research, 
regarding chromatin interactions at the MAF locus. A long intergenic non-coding 
RNA (lincRNA) ~139 kb upstream of MAF has been shown to form a loop with the 
MAF promoter and downregulate MAF expression in T lymphocytes [34]. The study 
showed that there was an inverse relationship between the lincRNA, named linc-
MAF-4, expression and MAF expression, and a 3C experiment subsequently showed 
peaks of interaction at the genomic sites. Downregulation of the linc-MAF-4 leads to 
an increase differentiation into TH2 cells, which MAF is a key driver of. The study 
shows that there is active regulation happening in this area – the linc-MAF-4 lies 
between the MAF promoter and the upstream region of interest in my study (see 
Figure 4.2). Different interactions (and the restriction thereof) may be controlling 
cell-type specificity. 
 
Figure 4.2 – Placement of l inc-MAF-4 in relat ion to MAF promoter 
and the three upstream regions of interest of this study. 
4.4 FUTURE DIRECTIONS FOR INVESTIGATING MAF’S ROLE 
IN SERUM URATE AND GOUT 
Aside from its possible role in multiple change nephrotic syndrome MCNS – which 
has not been particularly well-characterised – there is a serious lack of knowledge 
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is a transcription factor that has expression in the kidney of mice and zebrafish (both 
organisms are used as models of human disease) and has been shown to exhibit 
regulatory activity (in enhancing the promotion of Il23r). It has been identified as 
downstream of an association with serum urate concentrations in two large, 
independent GWAS analyses which between them investigated a range of ancestry, 
hinting that the association may be conserved for some reason. 
Furthermore, MAF is consistently shown to be involved in immunity – MAF is most-
often researched in an immune context and it is vital for immune cell differentiation. 
IL-1β is known to be a key mediator in gout, and MAF is a key regulator of the IL-4 
gene (a related but different gene). A paper published in 2002 [37] also clearly 
showed an association between IL-6 (a pro-inflammatory cytokine and released 
rapidly on stimulation) and decreased serum urate levels during an acute gout attack. 
The authors provided no real mechanism for this observation, but it was highly 
statistically significant and is deserving of consideration. Together, these seemingly 
small pieces of evidence build to a compelling case for investigating MAF – or rather, 
variants upstream that may be involved in regulation of MAF activity – and its role in 
serum urate, and then in gout. 
It is also possible that MAF regulates serum urate via glucose homeostasis in the 
pancreas [37]. All these possible mechanisms of action serve to reinforce the 
importance of characterising the interactions at the chromatin level, and the tissue-
specific expression patterns of regulatory elements. The variety of roles that MAF is 




be active in different tissues, regulating precise expression of MAF. To determine the 
exact role MAF plays in serum urate levels, it must be determined what interactions 
are occurring – whether it is with F1 or other regulatory elements – and which tissues 
these interactions occur. There is some excellent circumstantial evidence that MAF 
may well be the gene researchers are looking for – but which SNP is causal, and 
where does it affect MAF? 
A further possibility includes the use of CRISPR models to investigate the role of 
MAF in the kidney and serum urate levels. MAF knockout mice do not survive for 
long postpartum [44], but if tissue-specific MAF knockouts can be generated in 
zebrafish and/or mice, then the role of MAF specifically in the kidney can be 
observed. 
4.5 CONCLUSIONS AND SIGNIFICANCE 
This study has produced some promising results, some exciting results, and some 
inconclusive results. Although the bioinformatics meta-analysis did not identify causal 
SNPs that reached significance, it was close despite such a limited number of 
participants. This suggests something interesting may be yet to be discovered in that 
region, given a more powerful analysis. The luciferase assay provided intriguing 
results – F1 has enhancer activity and gout patients contain SNPs at this element that 
increase enhancer activity. Secondly, F2 may possibly have insulator activity – 




conducted. Finally, the 3C was unsuccessful and inconclusive – with more 
troubleshooting and a positive control there may be something to be found in future. 
Gout is a rising problem, both globally and particularly in NZ. To date we 
understand much of the physiology and epidemiology of gout, but many questions 
remain regarding the genetics and heritability of such a common, complex disease. 
GWAS analyses are a powerful tool in researching genetic association, but must be 
supported by empirical research if we are to realise their true value. Correlation is 
not evidence for causation, and so we must take the candidates GWAS provide and 
use them to untangle the knot that is complex disease.  
Variation in non-coding DNA is no longer considered to be inconsequential, and 
such variation has been increasingly shown to have important properties regarding 
the spatiotemporal regulation of genes. From the pool of candidates GWAS have 
already associated with serum urate concentration, variants in proximity to the MAF 
gene are worthy of further investigation. Variants associated with serum urate levels 
that reside upstream of MAF may have an important effect on regulating MAF 
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6.1 APPENDIX I - MATERIALS 
All solutions were made using sterile milli-Q water unless otherwise stated. The pH 
adjustments were made using 1 M HCl or NaOH. 
TABLE 6.1 -  Chemicals,  reagents and consumables used in this project  
Chemical (abbreviation) Manufacturer 
1 kb plus DNA ladder Invitrogen, US 
100 mM dNTPs Invitrogen, US 
Agar Bacteriological Oxoid Ltd, UK 
Ampicillin Sigma-Aldrich, US 
Bacto™ Tryptone Bectone Dickinson and Co, US 
Chloroform BDH Chemicals, UK 
Cutsmart buffer New England Biolabs, UK 
Dual-Glo® Luciferase Assay System Invitrogen, US 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
Gibco, ThermoFisher Scientific, US 
Ethanol Scharlab, Spain 
Ethidium bromide Merck, US 
Fetal bovine serum (FBS), NZ origin Gibco, ThermoFisher Scientific, US 
Formaldehyde ThermoFisher Scientific, US 
Gateway LR Clonase II enzyme mix Invitrogen, US 
Glycine Fisher Chemical, US 
Hydrochloric acid BDH Prolabo, UK 
Lipofectamine® 3000 Invtitrogen, US 
Linear polyacrylamide (LPA) ThermoFisher Scientific, US 
Magnesium chloride (MgCl2) Invitrogen, US 
Msp I New England Biolabs, UK 
NucleoSpin® Plasmid Miniprep kit Macherey-Nagel, Germany 
NucleoSpin® RNA extraction kit Macherey-Nagel, Germany 
NP-40 Sigma-Aldrich, US 
Opti-MEM™ reduced serum media Gibco, ThermoFisher Scientific, US 
P3000 ThermoFisher Scientific, US 
PCR buffer Invitrogen, US 
Phenol:chloroform Sigma-Aldrich, US 




Chemical (abbreviation) Manufacturer 
Protease inhibitor tablets Roche, US 
Proteinase K0 Invitrogen, US 
qScript™ cDNA SuperMix Quanta Biosciences, US 
RNase A Invitrogen, US 
Sodium chloride VMR Porlabo, UK 
Sodium dodecyl sulfate (SDS) ThermoFisher Scientific, US 
Sybr (Kapa) Kapa Biosystems, US 
Sybr® Green (Takara) ThermoFisher Scientific, US 
T4 ligase Invitrogen, US 
T4 ligase buffer Invitrogen, US 
Triton X-100 Sigma-Aldrich, US 
Trypan blue stain Signma-Aldrich, US 
Trypsin-EDTA (0.5%), no phenol red Gibco, ThermoFisher Scientific, US 
Ultrapure™ Agarose ThermoFisher Scientific, US 
Ultrapure™ DNase/RNase-free water ThermoFisher Scientific, US 
Ultrapure™ Tris ThermoFisher Scientific, US 
X-gal Sigma-Aldrich, US 
Yeast extract Oxoid Ltd, UK 
Zymoclean™ Gel DNA Recovery Kit Zymo Research, US 
 
 
Table 6.2 -  Solutions and buffers used in this project 
Solution/buffer Recipe 
1.5% agarose gel 1.5 g Ultrapure™ Agarose dissolved in 
100 ml 1x TBE, with 10 µl ethidium 
bromide 
Luria-Bertani (LB) medium 10 g tryptone, 5 g yeast extract, 10 g 
sodium chloride, 1 L milli-Q water. 
Sterilise by autoclaving. 
LB agar LB medium with 3 g agar bacteriological. 
Sterilise by autoclaving. 
Lysis buffer 100 µl 1M Tris-HCl (pH 8.0), 20 µl5M 
NaCl, 100 µl 20% NP-40, 1 protease 
inhibitor tablet. Make up to 30 ml with 
milli-Q water. 







6.2 APPENDIX II – PRIMER LIST 
All primers were synthesised by Integrated DNA Technologies. 
Table 6.3 -  Primer sequences used in this project,  l isted 5´to 3´ 
Primer Sequence 
MAF expression assay primers  
























3C qPCR primers  












6.3 APPENDIX III – MAF EXPRESSION ASSAY STANDARD 
CURVES 
Standard curves for each of the MAF expression primers are shown in Figure 5.1, 
with gradients and efficiencies presented in Table 5.4.  
 
Figure 6.1 -  Standard curves for MAF  expression assay. Log 
concentration is plotted along the x axis, with CP values plotted on the y axis. 
"
Table 6.4 -  Gradient of standard curve graphs and primer eff iciencies 
Primer Gradient of standard curve R2 Primer efficiency 
MAF -2.053 0.81046 125.44% 
MAF1 -1.559 0.86384 200.62% 

























6.4 APPENDIX IV – CLONING TROUBLESHOOTING AND 
LUCIFERASE OPTIMISATION 
6.4.1 Cloning troubleshooting 
To investigate the functional ability of F1 and F2, a luciferase assay was carried out to 
detect enhancer ability.!The first stage of this assay is the recombination of F1 (both 
with and without the two SNPs present in gout patients, referred to F1SNP and 
F1WT respectively) and F2 into pGL4.23-GW, using the Gateway cloning system. 
This requires efficient recombination between the two plasmids (TOPO and 
pGL4.23-GW), followed by efficient transformation of competent E. coli, without 
failure of the plasmids or cell. 
A few problems were struck at the start of this assay. Despite extreme caution with 
aseptic technique, few colonies were produced with the expected recombinants 
(according to sequencing results) and the negative control consistently yielded 
colonies. Once technique was ruled out and it was determined that other members of 
the lab group were also unsuccessful in their cloning attempts, a restriction digest was 
designed to determine what plasmids were present in the colonies that were growing. 
Plasmid DNA extracted from three colonies each of the three test plates (F1WT, 
F1SNP and F2) were subjected to a restriction digest. Unfortunately the pGL4.23-
GW sequence is not available in its entirety, so estimates were made to produce a 




TABLE 6.5 – Expected results of restrict ion digest to characterise 
plasmids present in transformed colonies 
* -- = not tested 
The results of the digest are presented in Figure 6.2, and show that all the extracted 
plasmids bar one were identical to pGL4.23-GW. One recombinant colony had 
been produced out of the nine tested. Theoretically it should be impossible for non-
recombinant plasmids to propogate in this bacteria – the Gateway cassette contains a 
toxin gene which this bacterial strain was not resistant to, so if it had not recombined 
then the cassette would still be present and no colonies should be produced. If 
TOPO vector alone had been transformed the cells would also die, as the TOPO 
vector contains spectinomycin resistance, yet the cells were plated onto ampicillin. 
These results suggested an inefficient recombination, or, more likely, a problem with 
the pGL4.23-GW plasmid stock. 
 pGL4.23-GW F1WT F1SNP F2 






PstI One linear fragment -- One linear 
fragment 
Two bands 





FIGURE 6.2 -  Agarose gels showing the results of a restrict ion digest in 
cloned DNA. A) shows the results of the XhoI digest – this should produce a 
linear fragment in pGL4.23-GW and supercoiled DNA in all other fragments. The 
yellow arrow indicates the pGL4.23-GW band, while the blue arrow indicates a single 
F1WT colony plasmid DNA. B) The red line on this gel indicates the results of the 
PstI digest, and the yellow arrows once again indicate pGL4.23-GW. The two 
remaining bands (uncovered by the red line) are undigested DNA. C) The purple 
line indicates the results of the PstI + StuI digest, yellow arrows indicate pGL4.23-
GW and the blue arrows again indicate an F1WT plasmid, the same one as in Gel 









6.4.2 Optimisation of luciferase recombination 
To optimise the recombination reaction, instead of mixing the TOPO and pGL4.23-
GW plasmids in a 1:3 ratio as had been done previously, they were instead mixed in 
a 1:1 ratio. The reaction mixture was also made up to 5 µL using Milli-Q H2O. It 
also transpired that the pGL4.23-GW stocks used had originally been cultured in 
only ampicillin – the plasmid contains ampicillin resistance, while the Gateway 
cassette contains chloramphenicol resistance. Possibly without selective pressure to 
maintain the Gateway cassette, it was spontaneously lost in some cases. Those 
plasmids may have outgrown others containing the cassette, without the associated 
metabolic cost of producing the ccdB toxin. To remedy this, the original pGL4.23-
GW stock (the first culture received) was re-cultured in the appropriate antibiotic 
conditions by Amarni Thomas. 
This troubleshooting solved the problem with colonies in the negative control and 
colonies were selected for monoclonal culturing and plasmid purification. 
Sequencing confirmed that the plasmids were successful recombinants and contained 
the correct fragments. 
6.5 APPENDIX V – 3C SEQUENCING RESULTS 
The figures below show the sequencing results from the final 3C qPCR replicate 
(section 3.4.7). In all three figures, The top part of the figure shows the sequence as 
displayed in 4Peaks, while the bottom part of the figure shows this sequence aligned 




bait primer, used to sequence the DNA, is also shown. The sequence itself is 
generally poor with many ambigious reads or multiple peaks at bases. In addition, 
there is very little consensus sequence between the two (shown as a long green bar), 
supporting the idea that more than one sequence has been amplified during both the 
qPCR and during the sequencing reaction. 
FIGURE 6.3 – Sequencing results and alignment of 1.1 primers in 
MCF10A 3C DNA.  
"
FIGURE 6.4 -  Sequencing results and alignment of 3.4 primers in 
MCF10A 3C DNA.  
"
FIGURE 6.5 -  Sequencing results and alignment of 3.1 primers in 
HEK293 3C DNA.  
"
"
